

[19] Patents Registry
The Hong Kong Special Administrative Region
香港特別行政區
專利註冊處

[11] 1237666 B
EP 3169341 B1

[12] **STANDARD PATENT (R) SPECIFICATION**
轉錄標準專利說明書

[21] Application no. 申請編號
17111761.5
[22] Date of filing 提交日期
14.11.2017

[51] Int. Cl.
A61K 35/768 (2015.01) C07K 16/18 (2006.01)

[54] ONCOLYTIC VIRUS FOR EXPRESSION OF IMMUNE CHECKPOINT MODULATORS
用於表達免疫檢查點調節因子的溶瘤病毒

[30] Priority 優先權
16.07.2014 EP 14306153.9
[43] Date of publication of application 申請發表日期
20.04.2018
[45] Date of publication of grant of patent 批予專利的發表日期
20.03.2020
[86] International application no. 國際申請編號
PCT/EP2015/066263
[87] International publication no. and date 國際申請發表編號及日期
WO2016/008976 21.01.2016
EP Application no. & date 歐洲專利申請編號及日期
EP 15738359.7 16.07.2015
EP Publication no. & date 歐洲專利申請發表編號及日期
EP 3169341 24.05.2017
Date of grant in designated patent office 指定專利當局批予專利日期
05.06.2019

[73] Proprietor 專利所有人
Transgene SA
Parc d'Innovation Boulevard Gonthier d'Andernach
67400 Illkirch Graffenstaden
FRANCE
[72] Inventor 發明人
SILVESTRE, Nathalie
GEIST, Michel
RITTNER, Karola
MARCHAND, Jean-Baptiste
THIOUDELLET, Christine
[74] Agent and / or address for service 代理人及/或送達地址
SPRUSON & FERGUSON (HONG KONG) LIMITED
5001 Hopewell Centre
183 Queen's Road East, Wan Chai
HONG KONG



(11)

EP 3 169 341 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:
05.06.2019 Bulletin 2019/23

(51) Int Cl.:
A61K 35/768 ^(2015.01) **C07K 16/18** ^(2006.01)

(21) Application number: **15738359.7**

(86) International application number:
PCT/EP2015/066263

(22) Date of filing: **16.07.2015**

(87) International publication number:
WO 2016/008976 (21.01.2016 Gazette 2016/03)

(54) ONCOLYTIC VIRUS FOR EXPRESSION OF IMMUNE CHECKPOINT MODULATORS

ONKOLYTISCHES VIRUS ZUR EXPRESSION VON IMMUNOLOGISCHEN PRÜFPUNKTMODULATOREN

VIRUS ONCOLYTIQUES POUR L'EXPRESSION DE MODULATEURS DE POINTS DE CONTRÔLE IMMUNITAIRE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: **16.07.2014 EP 14306153**

(43) Date of publication of application:
24.05.2017 Bulletin 2017/21

(73) Proprietor: **Transgene SA**
67400 Illkirch Graffenstaden (FR)

(72) Inventors:
• **SILVESTRE, Nathalie**
F-67120 Ergersheim (FR)
• **GEIST, Michel**
F-67170 Brumath (FR)
• **RITTNER, Karola**
F-67100 Strasbourg (FR)
• **MARCHAND, Jean-Baptiste**
F-67210 Obernai (FR)
• **THIOUDELLET, Christine**
F-67000 Strasbourg (FR)

(74) Representative: **Regimbeau**
20, rue de Chazelles
75847 Paris Cedex 17 (FR)

(56) References cited:
WO-A1-2009/065546 WO-A1-2014/047350

- **J D DIAS ET AL: "Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4", GENE THERAPY, 10 November 2011 (2011-11-10), XP055015331, ISSN: 0969-7128, DOI: 10.1038/gt.2011.176**
- **J. D. DIAS ET AL: "Targeted Chemotherapy for Head and Neck Cancer with a Chimeric Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1", CLINICAL CANCER RESEARCH, vol. 16, no. 9, 13 April 2010 (2010-04-13), pages 2540-2549, XP055214478, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-09-2974**
- **T DU ET AL: "Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers", CANCER GENE THERAPY, vol. 21, no. 8, 18 July 2014 (2014-07-18), pages 340-348, XP055214039, ISSN: 0929-1903, DOI: 10.1038/cgt.2014.34**
- **CHRISTINE E ENGELAND ET AL: "CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy", MOLECULAR THERAPY, vol. 22, no. 11, 26 August 2014 (2014-08-26), pages 1949-1959, XP055158410, ISSN: 1525-0016, DOI: 10.1038/mt.2014.160**
- **MAXINE BAUZON ET AL: "Armed Therapeutic Viruses - A Disruptive Therapy on the Horizon of Cancer Immunotherapy", FRONTIERS IN IMMUNOLOGY, vol. 5, 1 February 2014 (2014-02-01), XP055214432, DOI: 10.3389/fimmu.2014.00074**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 169 341 B1

- **DON B GAMMON ET AL: "Vaccinia Virus-Encoded Ribonucleotide Reductase Subunits Are Differentially Required for Replication and Pathogenesis", PL O S PATHOGENS (PRINT), PUBLIC LIBRARY OF SCIENCE, US, vol. 6, no. 7, 8 July 2010 (2010-07-08), pages e1000984-1, XP008150295, ISSN: 1553-7366, DOI: 10.1371/JOURNAL.PPAT.1000984**
- **Kyle G. Potts ET AL: "Oncolytic Viruses in the Treatment of Bladder Cancer", Advances in Urology, vol. 2012, 1 January 2012 (2012-01-01), pages 1-11, XP055443442, ISSN: 1687-6369, DOI: 10.1155/2012/404581**

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

Description**Field of the invention**

[0001] The present invention generally relates to the field of oncolytic virotherapy and more specifically to compositions and methods to treat, prevent, or inhibit proliferative diseases, especially cancer. Embodiments include an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s), as defined in the claims. Embodiments also include a pharmaceutical composition comprising such oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers, as defined in the claims.

[0002] Cancer is caused by both external factors (e.g. tobacco, infectious organisms, alimentary habits, chemicals, and radiation) and internal factors (e.g. inherited mutations, hormones, immune conditions, and mutations that occur from metabolism). Each year, cancer is diagnosed in more than 12 million subjects worldwide. In industrialized countries, approximately one person out five will die of cancer. Although a vast number of chemotherapeutics exist, they are often ineffective, especially against malignant and metastatic tumors that establish at a very early stage of the disease. Moreover, antitumor immunity is often ineffective due to the fact that tumor cells have evolved mechanisms to escape host defense. One of the major mechanisms of immune suppression is a process known as "T-cell exhaustion", which results from chronic exposure to antigens and is characterized by the upregulation of inhibitory receptors. These inhibitory receptors serve as immune checkpoints in order to prevent uncontrolled immune reactions. Various immune checkpoints acting at different levels of T cell immunity have been described in the literature, including programmed cell death protein 1 (PD-1) and its ligands PD-L1 and PD-L2, CTLA-4 (cytotoxic T-lymphocyte associated protein-4), LAG3, B and T lymphocyte attenuator, T-cell immunoglobulin, mucin domain-containing protein 3 (TIM-3), and V-domain immunoglobulin suppressor of T cell activation.

[0003] Whatever the mechanism of action, these immune checkpoints can inhibit the development of an efficient anti-tumor immune response. There is increasing interest in the possible therapeutic benefits of blocking such immune checkpoints as a means of inhibiting immune system tolerance to tumors and thus rescue exhausted antitumor T cells (Leach et al., 1996, Science 271: 1734-6). A vast number of antagonistic antibodies have been developed during the last decade (e.g. anti Tim3, -PD-L1, -CTLA-4, -PD1, etc) and most importantly, some have been associated with objective clinical responses in cancer patients. Antibodies targeting CTLA-4 are already marketed (e.g. Ipilimumab, Yervoy, Bristol-Myers Squibb) for metastatic melanoma. BMS reported that from 1800 melanoma patients treated with ipilimumab 22% are still alive 3 years later. Antibody therapies with anti PD-L1 (e.g. MPDL3280A, Roche), anti PD-1 (e.g. Nivolumab, BMS) are also ongoing.

[0004] Another therapeutic approach that is emerging in the field of cancer is oncolytic viruses (Hermiston, 2006, Curr. Opin. Mol. Ther. 8: 322-30). Oncolytic viruses are capable of selective replication in dividing cells (e.g. cancer cell) while leaving non dividing cells (e.g. normal cells) unharmed. As the infected dividing cells are destroyed by lysis, they release new infectious virus particles to infect the surrounding dividing cells. Cancer cells are ideal hosts for many viruses because they have the antiviral interferon pathway inactivated or have mutated tumor suppressor genes that enable viral replication to proceed unhindered (Chernajovsky et al., 2006, British Med. J. 332: 170-2). A number of viruses including adenovirus, reovirus, measles, herpes simplex, Newcastle disease virus and vaccinia have now been clinically tested as oncolytic agents.

[0005] Some viruses are naturally oncolytic (such as reovirus and the Seneca valley picornavirus) while others are engineered for tumor selectivity by modifying the viral genome. Such modifications include functional deletions in essential viral genes, the use of tumor- or tissue-specific promoters to control the viral gene expression and tropism modification to redirect virus to the cancer cell surface.

[0006] The first oncolytic virus to be approved by a regulatory agency was a genetically modified adenovirus named H101 (Shanghai Sunway Biotech) that gained approval in 2005 from China's State Food and Drug Administration (SFDA) for the treatment of head and neck cancer. Another oncolytic adenovirus, named ONYX-015 is in ongoing clinical trials for the treatment of various solid tumors (in phase III for the treatment of recurrent head and neck cancer) (Cohen et al., 2001, Curr. Opin. Investig. Drugs 2: 1770-5). As another example, oncolytic herpes simplex 1 (T-VEC) was genetically engineered to attenuate the virus virulence, increase selectivity for cancer cells and enhance antitumor immune response (through GM-CSF expression). Clinical efficacy in unresectable melanoma has been demonstrated in Phase II and Phase III clinical trials (Senzler et al, 2009, J. Clin. Oncol. 27: 5763-71).

[0007] Vaccinia viruses (VV) possess many of the key attributes necessary for use in oncolytic virotherapy such as natural tropism for tumors, strong lytic ability, short life cycle with rapid cell-to-cell spread, highly efficient gene expression and a large cloning capacity. In addition, they have been delivered to millions of individuals during the smallpox eradication campaign without major safety concerns. In this respect, a TK and VGF double deleted VV (Wyeth strain) expressing GM-CSF (named JX-963) showed significant cancer selectivity in tumor bearing mice (Thorne et al., 2007, J Clin Invest. 117: 3350-8). On the same line, JX-594, a TK-deleted VV (Wyeth strain) armed with GM-CSF, has shown promising

clinical data, and a randomized Phase III trial in hepatocellular carcinoma is expected to start soon.

[0008] Combination therapies involving oncolytic virus and immune checkpoint inhibitors have been described in the literature. WO2014/022138 describes the combination of irradiated tumor cells, an oncolytic adenovirus and an anti CTLA4 antibody for use for treating bladder or prostate cancer. WO2014/047350 envisages a recombinant oncolytic virus with a gene encoding an anti-PD-1 antibody inserted in the viral genome without providing any working example that would support utility of such an oncolytic virus.

Technical problem

[0009] One may expect that cancer will continue to be a serious global health threat for many years due to the high number of causal factors that may act together or separately to initiate or promote the development of a cancer. Moreover, malignant and especially metastatic tumors are often resistant to conventional therapies explaining the significant morbidity of some cancers.

[0010] Thus, there is an important need to develop more effective approaches, for improving prevention and treatment of such proliferative diseases, and especially metastatic cancers. The present invention provides a unique product combining oncolysis for killing dividing cells and immune checkpoint for breaking cancer-associated immune tolerance.

[0011] This technical problem is solved by the provision of the embodiments as defined in the claims.

[0012] Other and further aspects, features and advantages will be apparent from the following description of the presently preferred embodiments or examples. These embodiments or examples are given for the purpose of disclosure.

Summary of the present invention and the present disclosure

[0013] The present invention concerns an oncolytic virus comprising inserted in its genome a nucleic acid molecule encoding one or more immune checkpoint modulator(s), wherein said oncolytic virus is an oncolytic vaccinia virus defective for Ribonucleotide reductase (RR) activity resulting from inactivating mutations in the viral I4L gene.

[0014] The present disclosure more generally concerns an oncolytic virus comprising inserted in its genome one or more nucleic acid molecule(s) encoding one or more immune checkpoint modulator(s).

[0015] The oncolytic virus is preferably selected from the group consisting of reovirus, New Castle Disease virus (NDV), vesicular stomatitis virus (VSV), measles virus, influenza virus, Sinbis virus, adenovirus, poxvirus and herpes virus (HSV) and the like. The oncolytic virus may be a vaccinia virus. Preferably, the vaccinia virus is engineered to lack thymidine kinase activity (e.g. the genome of said VV has an inactivating mutation in J2R gene to produce a defective TK phenotype). Alternatively or in combination, the vaccinia virus is engineered to lack RR activity (e.g. the genome of said VV has an inactivating mutation in I4L and/or F4L gene to produce a defective RR phenotype). In the invention, the oncolytic virus is an oncolytic vaccinia virus defective for Ribonucleotide reductase (RR) activity resulting from inactivating mutations in the viral I4L gene.

[0016] In one embodiment, the vaccinia virus further expresses at least one therapeutic gene, in particular a gene encoding a suicide gene product and/or an immunostimulatory protein.

[0017] In the invention, the encoded one or more immune checkpoint modulator(s) is preferably an antagonist molecule that antagonizes the activity of PD-1, PD-L1 PD-L2, LAG3, Tim3, BTLA and CTLA4. In one embodiment, the encoded one or more immune checkpoint modulator(s) is an antagonist molecule that antagonizes the activity of PD-1, PD-L1 or CTLA4 with a specific preference for an anti PD-1 antibody and/or an anti CTLA4 antibody.

[0018] The present invention and disclosure further provide a composition comprising said oncolytic virus, eventually with a pharmaceutical acceptable vehicle. In one embodiment, the composition is formulated for intravenous or intratumoral administration.

[0019] The present disclosure also concerns the use of said oncolytic virus or composition thereof for treating a proliferative disease as well as a method of treatment relying on the administration of an effective amount of said oncolytic virus or composition thereof. For example, the proliferative disease treated by the method of the invention is cancer and especially melanoma, renal cancer, prostate cancer, breast cancer, colorectal cancer, lung cancer and liver cancer. For example, the use or method comprises an additional step in which a pharmaceutically acceptable amount of a prodrug is administered to said mammal. The administration of said prodrug takes place preferably at least 3 days after the administration of said oncolytic virus or virus composition.

[0020] The present invention also concerns an oncolytic virus or a pharmaceutical composition comprising an effective amount of said oncolytic virus and a pharmaceutical acceptable vehicle, for use for treating a proliferative disease, preferably a cancer, and more preferably a cancer selected from the group consisting of melanoma, renal cancer, prostate cancer, breast cancer, colorectal cancer, lung cancer and liver cancer, wherein said oncolytic virus comprises inserted in its genome a nucleic acid molecule encoding one or more immune checkpoint modulator(s), wherein said oncolytic virus is an oncolytic vaccinia virus defective for Ribonucleotide reductase (RR) activity resulting from inactivating mutations in the viral I4L gene.

Detailed description

[0021] The present invention is as defined in the claims.

[0022] The present disclosure more generally concerns an oncolytic virus comprising inserted in its genome one or more nucleic acid molecule(s) encoding one or more immune checkpoint modulator(s).

Definitions

[0023] As used herein, the terms "a" and "an" are used in the sense that they mean "at least one", "at least a first", "one or more" or "a plurality" of the referenced components or steps, unless the context clearly dictates otherwise. For example, the term "a cell" includes a plurality of cells, including mixtures thereof.

[0024] The term "one or more" refers to either one or a number above one (e.g. 2, 3, 4, 5, etc).

[0025] The term "and/or" wherever used herein includes the meaning of "and", "or" and "all or any other combination of the elements connected by said term".

[0026] The term "about" or "approximately" as used herein means within 20%, preferably within 10%, and more preferably within 5% of a given value or range.

[0027] As used herein, when used to define products, compositions and methods, the term "comprising" (and any form of comprising, such as "comprise" and "comprises"), "having" (and any form of having, such as "have" and "has"), "including" (and any form of including, such as "includes" and "include") or "containing" (and any form of containing, such as "contains" and "contain") are open-ended and do not exclude additional, unrecited elements or method steps. Thus, a polypeptide "comprises" an amino acid sequence when the amino acid sequence might be part of the final amino acid sequence of the polypeptide. Such a polypeptide can have up to several hundred additional amino acids residues. "Consisting essentially of" means excluding other components or steps of any essential significance. Thus, a composition consisting essentially of the recited components would not exclude trace contaminants and pharmaceutically acceptable carriers. A polypeptide "consists essentially of" an amino acid sequence when such an amino acid sequence is present with eventually only a few additional amino acid residues. "Consisting of" means excluding more than trace elements of other components or steps. For example, a polypeptide "consists of" an amino acid sequence when the polypeptide does not contain any amino acids but the recited amino acid sequence.

[0028] The terms "polypeptide", "peptide" and "protein" refer to polymers of amino acid residues which comprise at least nine or more amino acids bonded via peptide bonds. The polymer can be linear, branched or cyclic and may comprise naturally occurring and/or amino acid analogs and it may be interrupted by non-amino acids. As a general indication, if the amino acid polymer is more than 50 amino acid residues, it is preferably referred to as a polypeptide or a protein whereas if it is 50 amino acids long or less, it is referred to as a "peptide".

[0029] Within the context of the present disclosure, the terms "nucleic acid", "nucleic acid molecule", "polynucleotide" and "nucleotide sequence" are used interchangeably and define a polymer of any length of either polydeoxyribonucleotides (DNA) (e.g. cDNA, genomic DNA, plasmids, vectors, viral genomes, isolated DNA, probes, primers and any mixture thereof) or polyribonucleotides (RNA) (e.g. mRNA, antisense RNA, siRNA) or mixed polyribo-polydeoxyribonucleotides. They encompass single or double-stranded, linear or circular, natural or synthetic, modified or unmodified polynucleotides. Moreover, a polynucleotide may comprise non-naturally occurring nucleotides and may be interrupted by non-nucleotide components.

[0030] The term "analog" or "variant" as used herein refers to a molecule (polypeptide or nucleic acid) exhibiting one or more modification(s) with respect to the native counterpart. Any modification(s) can be envisaged, including substitution, insertion and/or deletion of one or more nucleotide/amino acid residue(s). Preferred are analogs that retain a degree of sequence identity of at least 80%, preferably at least 85%, more preferably at least 90%, and even more preferably at least 98% identity with the sequence of the native counterpart.

[0031] In a general manner, the term "identity" refers to an amino acid to amino acid or nucleotide to nucleotide correspondence between two polypeptide or nucleic acid sequences. The percentage of identity between two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps which need to be introduced for optimal alignment and the length of each gap. Various computer programs and mathematical algorithms are available in the art to determine the percentage of identity between amino acid sequences, such as for example the Blast program available at NCBI or ALIGN in Atlas of Protein Sequence and Structure (Dayhoffed, 1981, Suppl., 3:482-9). Programs for determining identity between nucleotide sequences are also available in specialized data base (e.g. Genbank, the Wisconsin Sequence Analysis Package, BESTFIT, FASTA and GAP programs). For illustrative purposes, "at least 80% identity" means 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%.

[0032] As used herein, the term "isolated" refers to a protein, polypeptide, peptide, polynucleotide, vector, etc., that is removed from its natural environment (i.e. separated from at least one other component(s) with which it is naturally associated or found in nature). For example, a nucleotide sequence is isolated when it is separated of sequences

normally associated with it in nature (e.g. dissociated from a genome) but it can be associated with heterologous sequences.

[0033] The term "obtained from", "originating" or "originate" is used to identify the original source of a component (e.g. polypeptide, nucleic acid molecule) but is not meant to limit the method by which the component is made which can be, for example, by chemical synthesis or recombinant means.

[0034] As used herein, the term "host cell" should be understood broadly without any limitation concerning particular organization in tissue, organ, or isolated cells. Such cells may be of a unique type of cells or a group of different types of cells such as cultured cell lines, primary cells and dividing cells. In the context of the disclosure, the term "host cells" include prokaryotic cells, lower eukaryotic cells such as yeast, and other eukaryotic cells such as insect cells, plant and mammalian (e.g. human or non-human) cells as well as cells capable of producing the oncolytic virus and/or the immune checkpoint modulator(s) for use herein. This term also includes cells which can be or has been the recipient of the vectors described herein as well as progeny of such cells.

[0035] As used herein, the term "oncolytic virus" refers to a virus capable of selectively replicating in dividing cells (e.g. a proliferative cell such as a cancer cell) with the aim of slowing the growth and/or lysing said dividing cell, either in vitro or in vivo, while showing no or minimal replication in non-dividing cells. Typically, an oncolytic virus contains a viral genome packaged into a viral particle (or virion) and is infectious (i.e. capable of infecting and entering into a host cell or subject). As used herein, this term encompasses DNA or RNA vector (depending on the virus in question) as well as viral particles generated thereof.

[0036] The term "treatment" (and any form of treatment such as "treating", "treat") as used herein encompasses prophylaxis (e.g. preventive measure in a subject at risk of having the pathological condition to be treated) and/or therapy (e.g. in a subject diagnosed as having the pathological condition), eventually in association with conventional therapeutic modalities. The result of the treatment is to slow down, cure, ameliorate or control the progression of the targeted pathological condition. For example, a subject is successfully treated for a cancer if after administration of an oncolytic virus as described herein, the subject shows an observable improvement of its clinical status.

[0037] The term "administering" (or any form of administration such as "administered") as used herein refers to the delivery to a subject of a therapeutic agent such as the oncolytic virus described herein.

[0038] As used herein, the term "proliferative disease" encompasses any disease or condition resulting from uncontrolled cell growth and spread including cancers as well as diseases associated to an increased osteoclast activity (e.g. rheumatoid arthritis, osteoporosis, etc) and cardiovascular diseases (restenosis that results from the proliferation of the smooth muscle cells of the blood vessel wall, etc). The term "cancer" may be used interchangeably with any of the terms "tumor", "malignancy", "neoplasm", etc. These terms are meant to include any type of tissue, organ or cell, any stage of malignancy (e.g. from a prelesion to stage IV)

[0039] The term "subject" generally refers to an organism for whom any product and method disclosed herein is needed or may be beneficial. Typically, the organism is a mammal, particularly a mammal selected from the group consisting of domestic animals, farm animals, sport animals, and primates. Preferably, the subject is a human who has been diagnosed as having or at risk of having a proliferative disease such as a cancer. The terms "subject" and "patients" may be used interchangeably when referring to a human organism and encompasses male and female. The subject to be treated may be a newborn, an infant, a young adult or an adult.

[0040] The term "combination" or "association" as used herein refers to any arrangement possible of various components (e.g. an oncolytic virus and one or more substance effective in anticancer therapy). Such an arrangement includes mixture of said components as well as separate combinations for concomitant or sequential administrations. The present disclosure encompasses combinations comprising equal molar concentrations of each component as well as combinations with very different concentrations. It is appreciated that optimal concentration of each component of the combination can be determined by the artisan skilled in the art.

[0041] The term "immune checkpoint modulator" refers to a molecule capable of modulating the function of an immune checkpoint protein in a positive or negative way (in particular the interaction between an antigen presenting cell (APC) or a cancer cell and a T effector cell). The term "immune checkpoint" refers to a protein directly or indirectly involved in an immune pathway that under normal physiological conditions is crucial for preventing uncontrolled immune reactions and thus for the maintenance of self-tolerance and/or tissue protection. The one or more immune checkpoint modulator(s) in use herein may independently act at any step of the T cell-mediated immunity including clonal selection of antigen-specific cells, T cell activation, proliferation, trafficking to sites of antigen and inflammation, execution of direct effector function and signaling through cytokines and membrane ligands. Each of these steps is regulated by counterbalancing stimulatory and inhibitory signals that in fine tune the response. In the context of the present invention and disclosure, the term encompasses immune checkpoint modulator(s) capable of down-regulating at least partially the function of an inhibitory immune checkpoint (antagonist) and/or immune checkpoint modulator(s) capable of up-regulating at least partially the function of a stimulatory immune checkpoint (agonist).

Oncolytic virus

[0042] The oncolytic virus of the present disclosure can be obtained from any member of virus identified at present time provided that it is oncolytic by its propensity to selectively replicate and kill dividing cells as compared to non-dividing cells. It may be a native virus that is naturally oncolytic or may be engineered by modifying one or more viral genes so as to increase tumor selectivity and/or preferential replication in dividing cells, such as those involved in DNA replication, nucleic acid metabolism, host tropism, surface attachment, virulence, lysis and spread (see for example Kim et al., 2001, Nat. Med. 7: 781; Wong et al., 2010, Viruses 2: 78-106). One may also envisage placing one or more viral gene(s) under the control of event or tissue-specific regulatory elements (e.g. promoter).

[0043] Exemplary oncolytic viruses include without limitation reovirus, Seneca Valley virus (SVV), vesicular stomatitis virus (VSV), Newcastle disease virus (NDV), herpes simplex virus (HSV), morbillivirus virus, retrovirus, influenza virus, Sinbis virus, poxvirus, adenovirus, or the like.

[0044] For example, the oncolytic virus of the present disclosure may be obtained from a reovirus. A representative example includes Reolysin (under development by Oncolytics Biotech; NCT01166542).

[0045] For example, the oncolytic virus of the present disclosure may be obtained from a Seneca Valley virus. A representative example includes NTX-010 (Rudin et al., 2011, Clin. Cancer Res. 17(4): 888-95).

[0046] For example, the oncolytic virus of the present disclosure may be obtained from a vesicular stomatitis virus (VSV). Representative examples are described in the literature (e.g. Stojdl et al., 2000, Nat. Med. 6(7): 821-5; Stojdl et al., 2003, Cancer Cell 4(4): 263-75).

[0047] For example, the oncolytic virus of the present disclosure may be obtained from a Newcastle disease virus. Representative examples include without limitation the 73-T PV701 and HDV-HUJ strains as well as those described in the literature (e.g. Phuangsab et al., 2001, Cancer Lett. 172(1): 27-36; Lorence et al., 2007, Curr. Cancer Drug Targets 7(2): 157-67; Freeman et al., 2006, Mol. Ther. 13(1): 221-8).

[0048] For example, the oncolytic virus of the present disclosure may be obtained from a herpes virus. The Herpesviridae are a large family of DNA viruses that all share a common structure and are composed of relatively large double-stranded, linear DNA genomes encoding 100-200 genes encapsided within an icosahedral capsid which is enveloped in a lipid bilayer membrane. Although the oncolytic herpes virus can be derived from different types of HSV, particularly preferred are HSV1 and HSV2. The herpes virus may be genetically modified so as to restrict viral replication in tumors or reduce its cytotoxicity in non-dividing cells. For example, any viral gene involved in nucleic acid metabolism may be inactivated, such as thymidine kinase (Martuza et al., 1991, Science 252: 854-6), ribonucleotide reductase (RR) (Boviatsis et al., Gene Ther. 1: 323-31; Mineta et al., 1994, Cancer Res. 54: 3363-66), or uracil-N-glycosylase (Pyles et al., 1994, J. Virol. 68: 4963-72). Another aspect involves viral mutants with defects in the function of genes encoding virulence factors such as the ICP34.5 gene (Chambers et al., 1995, Proc. Natl. Acad. Sci. USA 92: 1411-5). Representative examples of oncolytic herpes virus include NV1020 (e.g. Geevarghese et al., 2010, Hum. Gene Ther. 21(9): 1119-28) and T-VEC (Andtbacka et al., 2013, J. Clin. Oncol. 31, abstract number LBA9008).

[0049] For example, the oncolytic virus of the present disclosure may be obtained from a morbillivirus which can be obtained from the paramyxoviridae family, with a specific preference for measles virus. Representative examples of oncolytic measles viruses include without limitation MV-Edm (McDonald et al., 2006; Breast Cancer Treat. 99(2): 177-84) and HMWMAA (Kaufmann et al., 2013, J. Invest. Dermatol. 133(4): 1034-42).

[0050] For example, the oncolytic virus of the present disclosure may be obtained from an adenovirus. Methods are available in the art to engineer oncolytic adenoviruses. An advantageous strategy includes the replacement of viral promoters with tumor-selective promoters or modifications of the E1 adenoviral gene product(s) to inactivate its/their binding function with p53 or retinoblastoma (Rb) protein that are altered in tumor cells. In the natural context, the adenovirus E1B55kDa gene cooperates with another adenoviral product to inactivate p53 (p53 is frequently dysregulated in cancer cells), thus preventing apoptosis. Representative examples of oncolytic adenovirus include ONYX-015 (e.g. Khuri et al., 2000, Nat. Med 6(8): 879-85) and H101 also named Oncorine (Xia et al., 2004, Ai Zheng 23(12): 1666-70).

[0051] For example, the oncolytic virus of the present disclosure may be a poxvirus. As used herein the term "poxvirus" refers to a virus belonging to the Poxviridae family, with a specific preference for a poxvirus belonging to the Chordopoxviridae subfamily and more preferably to the Orthopoxvirus genus. Sequences of the genome of various poxviruses, for example, the vaccinia virus, cowpox virus, Canarypox virus, Ectromelia virus, Myxoma virus genomes are available in the art and specialized databases such as Genbank (accession number NC_006998, NC_003663, NC_005309, NC_004105, NC_001132 respectively).

[0052] Desirably, the oncolytic poxvirus is an oncolytic vaccinia virus. In the invention, the oncolytic poxvirus is an oncolytic vaccinia virus defective for Ribonucleotide reductase (RR) activity resulting from inactivating mutations in the viral I4L gene. Vaccinia viruses are members of the poxvirus family characterized by a 200kb double-stranded DNA genome that encodes numerous viral enzymes and factors that enable the virus to replicate independently from the host cell machinery. The majority of vaccinia virus particles is intracellular (IMV for intracellular mature virion) with a single lipid envelop and remains in the cytosol of infected cells until lysis. The other infectious form is a double enveloped

particle (EEV for extracellular enveloped virion) that buds out from the infected cell without lysing it.

[0053] Although it can derive from any vaccinia virus strain, Elstree, Wyeth, Copenhagen and Western Reserve strains are particularly preferred. The gene nomenclature used herein is that of Copenhagen vaccinia strain. It is also used herein for the homologous genes of other poxviridae unless otherwise indicated. However, gene nomenclature may be different according to the pox strain but correspondence between Copenhagen and other vaccinia strains are generally available in the literature.

[0054] Preferably, the oncolytic vaccinia virus of the present invention and disclosure is modified by altering for one or more viral gene(s). Said modification(s) preferably lead(s) to the synthesis of a defective protein unable to ensure the activity of the protein produced under normal conditions by the unmodified gene (or lack of synthesis). Modifications encompass deletion, mutation and/or substitution of one or more nucleotide(s) (contiguous or not) within the viral gene or its regulatory elements. Modification(s) can be made in a number of ways known to those skilled in the art using conventional recombinant techniques. Exemplary modifications are disclosed in the literature with a specific preference for those altering viral genes involved in DNA metabolism, host virulence, IFN pathway (see e.g. Guse et al., 2011, Expert Opinion Biol. Ther. 11(5): 595-608) and the like.

[0055] More preferably, the oncolytic poxvirus of the present invention and disclosure is modified by altering the thymidine kinase-encoding gene (locus J2R). The TK enzyme is involved in the synthesis of deoxyribonucleotides. TK is needed for viral replication in normal cells as these cells have generally low concentration of nucleotides whereas it is dispensable in dividing cells which contain high nucleotide concentration.

[0056] Alternatively or in combination, the oncolytic poxvirus of the present disclosure is modified by altering at least one gene or both genes encoding Ribonucleotide reductase (RR). In the natural context, this enzyme catalyzes the reduction of ribonucleotides to deoxyribonucleotides that represents a crucial step in DNA biosynthesis. The viral enzyme is similar in subunit structure to the mammalian enzyme, being composed of two heterologous subunits, designed R1 and R2 encoded respectively by the I4L and F4L locus. Sequences for the I4L and F4L genes and their locations in the genome of various poxvirus are available in public databases, for example via accession number DQ437594, DQ437593, DQ377804, AH015635, AY313847, AY313848, NC_003391, NC_003389, NC_003310, M-35027, AY243312, DQ011157, DQ011156, DQ011155, DQ011154, DQ011153, Y16780, X71982, AF438165, U60315, AF410153, AF380138, U86916, L22579, NC_006998, DQ121394 and NC_008291. In the context of the disclosure, either the I4L gene (encoding the R1 large subunit) or the F4L gene (encoding the R2 small subunit) or both may be inactivated. For example, Gammon et al. (2010, PLOS Pathogens. 6(7)) describes mutant vaccinia virus strains deleted for the I4L gene and/or for the F4L gene. In the invention, the oncolytic vaccinia virus is defective for Ribonucleotide reductase (RR) activity resulting from inactivating mutations in the viral I4L gene.

[0057] Alternatively or in combination, other strategies may also be pursued to further increase the virus tumor-specificity. A representative example of suitable modification includes disruption of the VGF-encoding gene from the viral genome. VGF (for VV growth factor) is a secreted protein which is expressed early after cell infection and its function seems important for virus spread in normal cells. Another example is the disruption of the A56R gene coding for hemagglutinin, eventually in combination with TK deletion (Zhang et al., 2007, Cancer Res. 67: 10038-46). Disruption of interferon modulating gene(s) may also be advantageous (e.g. the B8R or B18R gene) or the caspase-1 inhibitor B13R gene. Another suitable modification comprises the disruption of the F2L gene which encodes the viral dUTPase involved in both maintaining the fidelity of DNA replication and providing the precursor for the production of TMP by thymidylate synthase (Broyles et al., 1993, Virol. 195: 863-5). Sequence of the vaccinia virus F2L gene is available in genbank via accession number M25392.

[0058] Preferably, the oncolytic virus of this invention and disclosure is a vaccinia virus defective for TK resulting from inactivating mutations in the J2R gene. Preferably, the oncolytic virus of this invention and disclosure is a vaccinia virus defective for both TK and RR activities resulting from inactivating mutations in both the J2R gene and the I4L and/or F4L gene(s) carried by the viral genome (e.g. as described in WO2009/065546 and Foloppe et al., 2008, Gene Ther., 15: 1361-71), wherein in the invention the oncolytic vaccinia virus is defective for Ribonucleotide reductase (RR) activity resulting from inactivating mutations in the viral I4L gene. Preferably, the oncolytic virus of this invention and disclosure is a vaccinia virus defective for dUTPase resulting from inactivating mutations in the F2L gene (e.g. as described in WO2009/065547), eventually in combination with disruption of at least one of TK and RR activities or both (resulting in a virus with inactivating mutations in the F2L; F2L and J2R gene; F2L and I4L; or F2L, J2R and I4L).

Therapeutic genes

[0059] In one example, the oncolytic virus of this invention and disclosure further expresses at least one therapeutic gene inserted in the viral genome. A "therapeutic gene" encodes a product capable of providing a biological activity when administered appropriately to a subject, which is expected to cause a beneficial effect on the course or a symptom of the pathological condition to be treated by either potentiating anti-tumor efficacy or reinforcing the oncolytic nature of the virus. In the context of the invention and disclosure, the therapeutic gene can be of mammal origin (e.g. human,

murine, rabbit, etc) or not (e.g. of bacterial, yeast or viral origin).

[0060] A vast number of therapeutic genes may be envisaged in the context of the invention and disclosure such as those encoding polypeptides that can compensate for defective or deficient proteins in the subject, or those that act through toxic effects to limit or remove harmful cells from the body or those that encode immunity conferring polypeptides. They may be native genes or genes obtained from the latter by mutation, deletion, substitution and/or addition of one or more nucleotides.

[0061] Advantageously, the oncolytic virus of the present invention and disclosure carries a therapeutic gene selected from the group consisting of genes encoding suicide gene products and immunostimulatory proteins.

Suicide gene

[0062] The term "suicide gene" refers to a gene coding for a protein able to convert a precursor of a drug into a cytotoxic compound. Suicide genes comprise but are not limited to genes coding protein having a cytosine deaminase activity, a thymidine kinase activity, an uracil phosphoribosyl transferase activity, a purine nucleoside phosphorylase activity and a thymidylate kinase activity. Examples of suicide genes and corresponding precursors of a drug comprising one nucleobase moiety are disclosed in the following table

Table 1

Suicide gene	prodrug
Thymidine Kinase	Ganciclovir; Ganciclovir elaidic acid ester; penciclovir; Acyclovir; Valacyclovir; (E)-5-(2-bromovinyl)-2'-deoxyuridine; zidovudine; 2'-Exo-methanocarbathymidine
Cytosine deaminase	5-Fluorocytosine
Purine nucleoside phosphorylase	6-Methylpurine deoxyriboside; Fludarabine
uracil phosphoribosyl transferase	5-Fluorocytosine; 5-Fluorouracil
thymidylate kinase.	Azidothymidine

[0063] Desirably, the suicide gene encodes a protein having at least a CDase activity. In the prokaryotes and lower eukaryotes (it is not present in mammals), CDase is involved in the pyrimidine metabolic pathway by which exogenous cytosine is transformed into uracil by means of a hydrolytic deamination. CDase also deaminates an analogue of cytosine, i.e. 5-fluorocytosine (5-FC), thereby forming 5-fluorouracil (5-FU), a compound which is highly cytotoxic when it is converted into 5-fluoro-UMP (5-FUMP). CDase encoding nucleic acid molecule can be obtained from any prokaryotes and lower eukaryotes such as *Saccharomyces cerevisiae* (FCY1 gene), *Candida Albicans* (FCA1 gene) and *Escherichia coli* (codA gene). The gene sequences and encoded CDase proteins have been published and are available in specialized data banks (SWISSPROT EMBL, Genbank, Medline and the like). Functional analogues of these genes may also be used. Such analogues preferably have a nucleic acid sequence having a degree of identity of at least 70%, advantageously of at least 80%, preferably of at least 90%, and most preferably of at least 95% with the nucleic acid sequence of the native gene.

[0064] Alternatively or in combination, the oncolytic virus of the invention and disclosure carries in its viral genome a suicide gene encoding a polypeptide having uracil phosphoribosyl transferase (UPRTase) activity. In prokaryotes and lower eukaryotes, uracil is transformed into UMP by the action of UPRTase. This enzyme converts 5-FU into 5-FUMP. By way of illustration, the nucleic acid sequences encoding the UPRTases from *E. coli* (Andersen et al., 1992, European J. Biochem. 204: 51-56), from *Lactococcus lactis* (Martinussen et al., 1994, J. Bacteriol. 176: 6457-63), from *Mycobacterium bovis* (Kim et al., 1997, Biochem. Mol. Biol. Internat. 41: 1117-24) and from *Bacillus subtilis* (Martinussen et al., 1995, J. Bacteriol. 177: 271-4) may be used in the context of the invention and disclosure. However, it is most particularly preferred to use a yeast UPRTase and in particular that encoded by the *S. cerevisiae* (FUR1 gene) whose sequence is disclosed in Kern et al. (1990, Gene 88: 149-57). Functional UPRTase analogues may also be used such as the N-terminally truncated FUR1 mutant described in EP998568 (with a deletion of the 35 first residues up to the second Met residue present at position 36 in the native protein) which exhibits a higher UPRTase activity than that of the native enzyme.

[0065] Preferably, the suicide gene inserted in the viral genome of the oncolytic virus of the present invention and disclosure encodes a polypeptide having CDase and UPRTase activities. Such a polypeptide can be engineered by fusion of two enzymatic domains, one having the CDase activity and the second having the UPRTase activity. Exemplary polypeptides include without limitation fusion polypeptides codA::upp, FCY1::FUR1 and FCY1::FUR1[Delta] 105 (FCU1)

and FCU1-8 described in WO96/16183, EP998568 and WO2005/07857. Of particular interest is the FCU1 suicide gene (or FCY1::FUR1[Delta] 105 fusion) encoding a polypeptide comprising the amino acid sequence represented in the sequence identifier SEQ ID NO: 1 of WO2009/065546. The present invention and disclosure encompass analogs of such polypeptides providing they retain the CDase, and/or UPRTase activities. It is within the reach of the skilled person to isolate the CDase and/or UPRTase -encoding nucleic acid molecules from the published data, eventually engineer analogs thereof and test the enzymatic activity in an acellular or cellular system according to conventional techniques (see e.g. EP998568).

Immunostimulatory therapeutic genes

[0066] As used herein, the term "immunostimulatory protein" refers to a protein which has the ability to stimulate the immune system, in a specific or non-specific way. A vast number of proteins are known in the art for their ability to exert an immunostimulatory effect. Examples of suitable immunostimulatory proteins in the context of the invention and disclosure include without limitation cytokines, with a specific preference for interleukins (e.g. IL-2, IL-6, IL-12, IL-15, IL-24), chemokines (e.g. CXCL10, CXCL9, CXCL11), interferons (e.g. IFN γ , IFN α), tumor necrosis factor (TNF), colony-stimulating factors (e.g. GM-CSF, C-CSF, M-CSF...), APC (for Antigen Presenting Cell)-exposed proteins (e.g. B7.1, B7.2 and the like), growth factors (Transforming Growth Factor TGF, Fibroblast Growth Factor FGF, Vascular Endothelial Growth Factors VEGF, and the like), MHC antigens of class I or II, apoptosis inducers or inhibitors (e.g. Bax, Bcl2, BclX...), cytostatic agents (p21, p16, Rb...), immunotoxins, antigenic polypeptides (antigenic polypeptides, epitopes, and the like) and markers (beta-galactosidase, luciferase...). Preferably, the immunostimulatory protein is an interleukin or a colony-stimulating factor, with a specific preference for GM-CSF.

Immune checkpoint modulator(s)

[0067] Immune checkpoints and modulators thereof as well as methods of using such compounds are described in the literature. In accordance with this invention and disclosure, the one or more immune checkpoint modulator(s) may independently be a polypeptide comprising a domain capable of binding the targeted immune checkpoint and/or inhibiting the binding of a ligand to said targeted immune checkpoint so as to exert an antagonist function (i.e. being capable of antagonizing an immune checkpoint-mediated inhibitory signal) or an agonist function (i.e. being capable of boosting an immune checkpoint-mediated stimulatory signal). Such one or more immune checkpoint modulator(s) can be independently selected from the group consisting of peptides (e.g. peptide ligands), soluble domains of natural receptors, RNAi, antisense molecules, antibodies and protein scaffolds.

[0068] Preferably, the immune checkpoint modulator is an antibody. In the context of the invention and disclosure, "antibody" ("Ab") is used in the broadest sense and encompasses naturally occurring and engineered by man as well as full length antibodies or functional fragments or analogs thereof that are capable of binding the target immune checkpoint or epitope (thus retaining the target-binding portion). The antibody encoded by the oncolytic virus of the invention and disclosure can be of any origin, e.g. human, humanized, animal (e.g. rodent or camelid antibody) or chimeric. It may be of any isotype (e.g. IgG1, IgG2, IgG3, IgG4, IgM isotype, etc). In addition, it may be glycosylated, partially glycosylated or non-glycosylated (e.g. by mutating one or more residue(s) within the site(s) of glycosylation). The term antibody also includes bispecific or multispecific antibodies so long as they exhibit the binding specificity described herein.

[0069] For illustrative purposes, full length antibodies are glycoproteins comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable region (VH) and a heavy chain constant region which is made of three CH1, CH2 and CH3 domains (eventually with a hinge between CH1 and CH2). Each light chain is comprised of a light chain variable region (VL) and a light chain constant region which comprises one CL domain. The VH and VL regions comprise hypervariable regions, named complementarity determining regions (CDR), interspersed with more conserved regions named framework regions (FR). Each VH and VL is composed of three CDRs and four FRs in the following order: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. The CDR regions of the heavy and light chains are determinant for the binding specificity.

[0070] As used herein, a "humanized antibody" refers to a non-human (e.g. murine, camel, rat, etc) antibody whose protein sequence has been modified to increase its similarity to a human antibody (i.e. produced naturally in humans). The process of humanization is well known in the art (see e.g. Presta et al., 1997, Cancer Res. 57(20): 4593-9; US 5,225,539; US 5,530,101; US 6,180,370; WO2012/110360). For example, the immune checkpoint antibody for use herein can be humanized by substituting one or more residue of the FR regions to look like human immunoglobulin sequence whereas the vast majority of the residues of the variable regions (especially the CDRs) are not modified and correspond to those of a non-human immunoglobulin. For general guidance, the number of these amino acid substitutions in the FR regions is typically no more than 20 in each variable region VH or VL.

[0071] As used herein, a "chimeric antibody" refers to an antibody comprising one or more element(s) of one species and one or more element(s) of another species, for example, a non-human antibody comprising at least a portion of a

constant region (Fc) of a human immunoglobulin.

[0072] Many forms of antibody can be expressed by the oncolytic virus of the invention and disclosure. Representative examples include without limitation Fab, Fab', F(ab')₂, dAb, Fd, Fv, scFv, di-scFv and diabody, etc.,. More specifically:

- (i) a Fab fragment represented by a monovalent fragment consisting of the VL, VH, CL and CH1 domains;
- (ii) a F(ab')₂ fragment represented by a bivalent fragment comprising two Fab fragments linked by at least one disulfide bridge at the hinge region;
- (iii) a Fd fragment consisting of the VH and CH1 domains;
- (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody,
- (v) a dAb fragment consisting of a single domain variable fragment (VH or VL domain);
- (vi) a single chain Fv (scFv) comprising the two domains of a Fv fragment, VL and VH, that are fused together, eventually with a linker to make a single protein chain (see e.g. Bird et al., 1988, Science 242: 423-6; Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85: 5879-83; US 4,946,778; US 5,258,498); and
- (vii) any other artificial antibody.

[0073] If needed, such fragments and analogs may be screened for functionality in the same manner as with intact antibodies (e.g. by standard ELISA assay).

[0074] Preferably, at least one of the one or more immune checkpoint modulator(s) encoded by the oncolytic virus of the present invention and disclosure is a monoclonal antibody, with a specific preference for a human (in which both the framework regions are derived from human germline immunoglobulin sequences) or a humanized antibody according to well-known humanization process.

[0075] Desirably, the one or more immune checkpoint modulator(s) encoded by the oncolytic virus of the present invention and disclosure antagonize(s) at least partially (e.g. more than 50%) the activity of inhibitory immune checkpoint(s), in particular those mediated by any of the following PD-1, PD-L1, PD-L2, LAG3, Tim3, BTLA and CTLA4, with a specific preference for a monoclonal antibody that specifically binds to any of such target proteins. The term "specifically binds to" refers to the capacity to a binding specificity and affinity for a particular target or epitope even in the presence of a heterogeneous population of other proteins and biologics. Thus, under designated assay conditions, the antibody in use in the invention and disclosure binds preferentially to its target and does not bind in a significant amount to other components present in a test sample or subject. Preferably, such an antibody shows high affinity binding to its target with an equilibrium dissociation constant equal or below 1×10^{-6} M (e.g. at least 0.5×10^{-6} , 1×10^{-7} , 1×10^{-8} , 1×10^{-9} , 1×10^{-10} , etc). Alternatively, the encoded one or more immune checkpoint modulator(s) of the present disclosure exert(s) an agonist function in the sense that it is capable of stimulating or reinforcing stimulatory signals, in particular those mediated by CD28 with a specific preference for any of ICOS, CD137 (4-1BB), OX40, CD27, CD40, GITR immune checkpoints. Standard assays to evaluate the binding ability of the antibodies toward immune checkpoints are known in the art, including for example, ELISAs, Western blots, RIAs and flow cytometry. The binding kinetics (e.g., binding affinity) of the antibodies also can be assessed by standard assays known in the art, such as by Biacore analysis.

[0076] Preferably, at least one of the one or more encoded checkpoint modulator(s) is a human or a humanized antibody capable of antagonizing an immune checkpoint involved in T cell-mediated response. A preferred example of immune checkpoint modulator is represented by a modulator capable of antagonizing at least partially the protein Programmed Death 1 (PD-1), and especially an antibody that specifically binds to human PD-1. PD-1 is part of the immunoglobulin (Ig) gene superfamily and a member of the CD28 family. It is a 55 kDa type 1 transmembrane protein expressed on antigen-experienced cells (e.g. activated B cells, T cells, and myeloid cells) (Agata et al., 1996, Int. Immunol. 8: 765-72; Okazaki et al., 2002, Curr. Opin. Immunol. 14: 391779-82; Bennett et al., 2003, J. Immunol. 170: 711-8). In normal context, it acts by limiting the activity of T cells at the time of inflammatory response, thereby protecting normal tissues from destruction (Topalian, 2012, Curr. Opin. Immunol. 24: 207-12). Two ligands have been identified for PD-1, respectively PD-L1 (programmed death ligand 1) and PD-L2 (programmed death ligand 2) (Freeman et al., 2000, J. Exp. Med. 192: 1027-34; Carter et al., 2002, Eur. J. Immunol. 32: 634-43). PD-L1 was identified in 20-50% of human cancers (Dong et al., 2002, Nat. Med. 8: 787-9). The interaction between PD-1 and PD-L1 resulted in a decrease in tumor infiltrating lymphocytes, a decrease in T-cell receptor mediated proliferation, and immune evasion by the cancerous cells (Dong et al., 2003, J. Mol. Med. 81: 281-7; Blank et al., 2005, Cancer Immunol. Immunother. 54: 307-314). The complete nucleotide and amino acid PD-1 sequences can be found under GenBank Accession No U64863 and NP_005009.2. A number of anti PD1 antibodies are available in the art (see e.g. those described in WO2004/004771; WO2004/056875; WO2006/121168; WO2008/156712; WO2009/014708; WO2009/114335; WO2013/043569; and WO2014/047350). Preferably, the oncolytic virus of the present invention and disclosure encodes and expresses an anti PD-1 antibody that is FDA approved or under advanced clinical development such as the ones marketed or developed under the names of Nivolumab (also termed BMS-936558 under development by Bristol Myer Squibb), Pembrolizumab (also termed MK-3475 under development by Merck), and Pidilizumab (also termed CT-011 under development by CureTech). The corresponding nucleotide sequences can be cloned or isolated according to standard techniques based

on the information disclosed in the available literature.

[0077] Another preferred example of immune checkpoint modulator suitable for expression by the oncolytic virus of the invention and disclosure is represented by a modulator capable of antagonizing at least partially the PD-1 ligand termed PD-L1, and especially an antibody that recognizes human PD-L1. A number of anti PD-L1 antibodies are available in the art (see e.g. those described in EP1907000). Preferred anti PD-L1 antibodies are FDA approved or under advanced clinical development (MPDL3280A under development by Genentech/Roche and BMS-936559 under development by Bristol Myer Squibb as well as anti-PD-L1 Fc fusions (e.g. AMP-224 developed by Medimmune and AstraZeneca).

[0078] One may also use an antagonist of the recently identified VISTA protein that was shown to negatively regulate T cell responses (Wang et al., 2011, J. Exp. Med. 208(3): 577-592). VISTA, also designated PD-1H and PD-L3, resembles members of the PD-L1 family. For example, anti-VISTA antagonists are described in US2013-0177557.

[0079] Still another preferred example of suitable immune checkpoint modulator is represented by a modulator capable of antagonizing at least partially the CTLA-4 protein, and especially an antibody that recognizes human CTLA-4. CTLA4 (for cytotoxic T-lymphocyte-associated antigen 4) also known as CD152 was identified in 1987 (Brunet et al., 1987, Nature 328: 267-70) and is encoded by the CTLA4 gene (Dariavach et al., Eur. J. Immunol. 18: 1901-5). CTLA4 is a member of the immunoglobulin superfamily of receptors. It is expressed on the surface of helper T cells where it primarily regulates the amplitude of the early stages of T cell activation. Recent work has suggested that CTLA-4 may function *in vivo* by capturing and removing B7-1 and B7-2 from the membranes of antigen-presenting cells, thus making these unavailable for triggering of CD28 (Qureshi et al., Science, 2011, 332: 600-3). The complete CTLA-4 nucleic acid sequence can be found under GenBank Accession No LI 5006. A number of anti CTLA-4 antibodies are available in the art (see e.g. those described in US 8,491,895). Preferred anti CTLA-4 antibodies in the context of this invention and disclosure are FDA approved or under advanced clinical development. One may cite more particularly ipilimumab marketed by Bristol Myer Squibb as Yervoy (see e.g. US 6,984,720; US 8,017,114), tremelimumab under development by Pfizer (see e.g. US 7,109,003 and US 8,143,379) and single chain anti-CTLA4 antibodies (see e.g. WO97/20574 and WO2007/123737).

[0080] The oncolytic virus of the present invention and disclosure may also express an immune checkpoint modulator for antagonizing the LAG3 receptor (see e.g. US 5,773,578).

[0081] Another example of suitable immune checkpoint modulator is represented by an OX40 agonist such as agonist ligand of OX40 (OX40L) (see e.g. US 5,457,035, US 7,622,444; WO03/082919) or an antibody directed to the OX40 receptor (see e.g. US 7,291,331 and WO03/106498).

[0082] Other examples of immune checkpoint modulators are represented by anti-KIR or anti-CD96 antibody targeting the inhibitory receptors harbored by CD8⁺ T cells and NK cells.

[0083] The present invention and disclosure encompass an oncolytic virus encoding more than one immune checkpoint modulator. A preferred example includes without limitation expression of an anti-CTLA-4 antibody and an anti-PD-1 antibody.

Expression of the one or more nucleic acid molecule(s) encoding the immune checkpoint modulator(s) and if any of the therapeutic genes inserted into the viral genome.

[0084] The immune checkpoint modulator-encoding nucleic acid molecule(s) and the therapeutic gene may be easily obtained by standard molecular biology techniques (e.g. PCR amplification, cDNA cloning, chemical synthesis) using sequence data accessible in the art and the information provided herein. Methods for cloning antibodies, fragments and analogs thereof are known in the art (see e.g. Harlow and Lane, 1988, Antibodies-A laboratory manual; Cold Spring Harbor Laboratory, Cold Spring Harbor NY). For example, the nucleic acid molecule (e.g. cDNA) encoding the light and heavy chains of the antibody or their CDRs may be isolated from the producing hybridoma (see e.g. Kohler and Milstein, 1975, Nature 256: 495-7; Cote et al., 1983, Proc. Natl. Acad. Sci. USA 80: 2026-30; Cole et al. in Monoclonal antibodies and Cancer Therapy; Alan Liss pp77-96), immunoglobulin gene libraries, or from any available source or the nucleotide sequence may be generated by chemical synthesis. Analogs and fragments may be generated using standard techniques of molecular biology.

[0085] The nucleic acid molecule(s) encoding the immune checkpoint modulator(s) and eventually the therapeutic gene(s) can independently be inserted at any location of the viral genome, with a specific preference for a non-essential locus. Insertion into the oncolytic virus can be performed by routine molecular biology, e.g. as described in Sambrook et al. (2001, Molecular Cloning-A Laboratory Manual, Cold Spring Harbor Laboratory). Insertion into an adenoviral vector or a poxviral vector can be performed through homologous recombination as described respectively in Chartier et al. (1996, J. Virol. 70: 4805-10) and Paul et al. (2002, Cancer gene Ther. 9: 470-7). For example, TK, RR and F2L genes as well as intergenic regions are particularly appropriate for insertion in oncolytic vaccinia virus and E3 and E4 regions for insertion in oncolytic adenovirus virus.

[0086] In addition, the encoding nucleotide sequences can be optimized for providing high level expression in a particular host cell or subject. It has been indeed observed that, the codon usage patterns of organisms are highly non-

random and the use of codons may be markedly different between different hosts. For example, the therapeutic gene may be from bacterial or lower eukaryote origin (e.g. the suicide gene), and thus have an inappropriate codon usage pattern for efficient expression in higher eukaryotic cells (e.g. human). Typically, codon optimization is performed by replacing one or more "native" (e.g. bacterial or yeast) codon corresponding to a codon infrequently used in the host organism of interest by one or more codon encoding the same amino acid which is more frequently used. It is not necessary to replace all native codons corresponding to infrequently used codons since increased expression can be achieved even with partial replacement.

[0087] Further to optimization of the codon usage, expression in the host cell or subject can further be improved through additional modifications of the nucleotide sequence(s). For example, various modifications may be envisaged so as to prevent clustering of rare, non-optimal codons being present in concentrated areas and/or to suppress or modify "negative" sequence elements which are expected to negatively influence expression levels. Such negative sequence elements include without limitation the regions having very high (>80%) or very low (<30%) GC content; AT-rich or GC-rich sequence stretches; unstable direct or inverted repeat sequences; R A secondary structures; and/or internal cryptic regulatory elements such as internal TATA-boxes, chi-sites, ribosome entry sites, and/or splicing donor/acceptor sites.

[0088] In accordance with the present invention and disclosure, each of the one or more nucleic acid molecule(s) encoding said immune checkpoint modulator(s) as well as the therapeutic gene(s) inserted in the genome of the oncolytic virus of the invention and disclosure is operably linked to suitable regulatory elements for its expression in a host cell or subject. As used herein, the term "regulatory elements" or "regulatory sequence" refers to any element that allows, contributes or modulates the expression of the encoding nucleic acid molecule(s) in a given host cell or subject, including replication, duplication, transcription, splicing, translation, stability and/or transport of the nucleic acid(s) or its derivative (i.e. mRNA). As used herein, "operably linked" means that the elements being linked are arranged so that they function in concert for their intended purposes. For example, a promoter is operably linked to a nucleic acid molecule if the promoter effects transcription from the transcription initiation to the terminator of said nucleic acid molecule in a permissive host cell.

[0089] It will be appreciated by those skilled in the art that the choice of the regulatory sequences can depend on such factors as the nucleic acid molecule itself, the virus into which it is inserted, the host cell or subject, the level of expression desired, etc. The promoter is of special importance. In the context of the invention and disclosure, it can be constitutive directing expression of the nucleic acid molecule in many types of host cells or specific to certain host cells (e.g. liver-specific regulatory sequences) or regulated in response to specific events or exogenous factors (e.g. by temperature, nutrient additive, hormone, etc) or according to the phase of a viral cycle (e.g. late or early). One may also use promoters that are repressed during the production step in response to specific events or exogenous factors, in order to optimize virus production and circumvent potential toxicity of the expressed polypeptide(s).

[0090] Promoters suitable for constitutive expression in mammalian cells include but are not limited to the cytomegalovirus (CMV) immediate early promoter (US 5,168,062), the RSV promoter, the adenovirus major late promoter, the phosphoglycerate kinase (PGK) promoter (Adra et al., 1987, Gene 60: 65-74), the thymidine kinase (TK) promoter of herpes simplex virus (HSV)-1 and the T7 polymerase promoter (WO98/10088). Vaccinia virus promoters are particularly adapted for expression in oncolytic poxviruses. Representative examples include without limitation the vaccinia 7.5K, H5R, 11K7.5 (Erbs et al., 2008, Cancer Gene Ther. 15(1): 18-28), TK, p28, p11, pB2R, pA35R and K1L promoters, as well as synthetic promoters such as those described in Chakrabarti et al. (1997, Biotechniques 23: 1094-7; Hammond et al, 1997, J. Virol Methods 66: 135-8; and Kumar and Boyle, 1990, Virology 179: 151-8) as well as early/late chimeric promoters. Promoters suitable for oncolytic measles viruses include without limitation any promoter directing expression of measles transcription units (Brandler and Tangy, 2008, CIMID 31: 271).

[0091] In particular, when the encoded immune checkpoint modulator(s) comprise(s) an antibody and especially a mAb, with a specific preference for an anti-PD1 antibody, expression of the heavy chain or fragment thereof is placed under the control of a promoter that is stronger than the one used for expressing light chain or fragment thereof. In particular, the promoter for use for expressing the heavy component provides at least 10%, at least 15%, at least 20%, at least 25%, or at least 30% more product as compared to expression of said light component. Appropriate promoters for expression can be tested *in vitro* (e.g. in a suitable cultured cell line) or *in vivo* (e.g. in a suitable animal model or in the subject). Examples of suitable promoters for expressing the heavy component of said immune checkpoint modulator comprise CMV, RSV and vaccinia virus pH5R and p11K7.5 promoters. Examples of suitable promoters for expressing the light component of said immune checkpoint modulator comprise PGK, beta-actin and vaccinia virus p7.5K and pA35R promoters.

[0092] Those skilled in the art will appreciate that the regulatory elements controlling the expression of the nucleic acid molecule(s) inserted into the viral genome may further comprise additional elements for proper initiation, regulation and/or termination of transcription (e.g. polyA transcription termination sequences), mRNA transport (e.g. nuclear localization signal sequences), processing (e.g. splicing signals), and stability (e.g. introns and non-coding 5' and 3' sequences), translation (e.g. an initiator Met, tripartite leader sequences, IRES ribosome binding sites, signal peptides, etc.).

[0093] When appropriate, it may be advantageous to include additional regulatory elements to facilitate expression,

trafficking and biological activity of at least one of gene inserted into the viral genome of the oncolytic virus of the invention and disclosure (i.e. the therapeutic gene(s) and/or the one or more immune checkpoint modulator(s)). For example, a signal peptide may be included for facilitating secretion from the infected cell. The signal peptide is typically inserted at the N-terminus of the protein immediately after the Met initiator. The choice of signal peptides is wide and is accessible to persons skilled in the art. One may also envisage addition of a trans-membrane domain to facilitate anchorage of the encoded protein(s) in a suitable membrane (e.g. the plasmic membrane) of the infected cells. The trans-membrane domain is typically inserted at the C-terminus of the protein just before or at close proximity of the STOP codon. A vast variety of trans-membrane domains are available in the art (see e.g. WO99/03885).

[0094] As an additional example, a peptide tag (typically a short peptide sequence able to be recognized by available antisera or compounds) may be also be added for following expression, trafficking or purification of the encoded gene product. A vast variety of tag peptides can be used in the context of the invention and disclosure including, without limitation, PK tag, FLAG octapeptide, MYC tag, HIS tag (usually a stretch of 4 to 10 histidine residues) and e-tag (US 6,686,152). The tag peptide(s) may be independently positioned at the N-terminus of the protein or alternatively at its C-terminus or alternatively internally or at any of these positions when several tags are employed. Tag peptides can be detected by immunodetection assays using anti-tag antibodies.

[0095] As another example, the glycosylation can be altered so as to increase biological activity of the encoded gene product (e.g. to increase). Such modifications can be accomplished, for example, by mutating one or more residues within the site(s) of glycosylation. Altered glycosylation patterns may increase the ADCC ability of antibodies and/or their affinity for their target.

[0096] Another approach that may be pursued in the context of the present invention and disclosure is coupling of the gene product encoded by the oncolytic virus of the invention and disclosure to an external agent such as a cytotoxic agent and/or a labelling agent. As used herein, the term "cytotoxic agent" refers to a compound that is directly toxic to cells, preventing their reproduction or growth such as toxins (e. g. an enzymatically active toxin of bacterial, fungal, plant or animal origin, or fragments thereof). As used herein, "a labeling agent" refers to a detectable compound. The labeling agent may be detectable by itself (e. g., radioactive isotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical modification of a substrate compound which is detectable. The coupling may be performed by genetic fusion between the gene product (therapeutic gene(s) and/or immune checkpoint modulator(s)) and the external agent.

[0097] Preferably, the oncolytic virus of the invention and disclosure is a vaccinia virus (preferably from the Copenhagen strain) defective for both TK and RR activities (e.g. resulting from inactivating mutations in both the viral J2R and I4L genes) in the genome of which is inserted a nucleic acid molecule encoding an anti-PD1 antibody. Desirably, the heavy and light chain elements (e.g. heavy and light chains for mAb expression, or variable fragments thereof for Fab and scFv expression) are respectively placed under the transcriptional control of the pH5R and p7.5K vaccinia promoters. Preferably, the anti-PD1-encoding nucleic acid molecule is inserted within TK locus of the viral genome. More preferably, said vaccinia virus is armed with a suicide gene with a special preference for the FCU1 suicide gene described herein. Even more preferably, the suicide gene (e.g. FCU1) is under the transcriptional control of the p11K7.5 vaccinia promoter. Still more preferably, the FCU1 placed under the control of the vaccinia virus promoter is inserted within TK locus of the virus genome.

[0098] In an alternative and also preferred example, the oncolytic virus of the disclosure is a vaccinia virus (preferably from the Wyeth strain) defective for TK activity (resulting from inactivating mutations in the virus J2R gene) in the genome of which is inserted a nucleic acid molecule encoding an anti-PD1 antibody. More preferably, said vaccinia virus is armed with an immunostimulatory therapeutic gene with a special preference for the human GM-CSF gene described herein. Even more preferably, the therapeutic gene (e.g. GM-CSF) is under the transcriptional control of a synthetic early-late promoter vaccinia promoter and is preferably inserted within TK locus.

[0099] Typically, the oncolytic virus of the present invention and disclosure is produced into a suitable host cell line using conventional techniques including culturing the transfected or infected host cell under suitable conditions so as to allow the production of infectious viral particles and recovering the produced infectious viral particles from the culture of said cell and optionally purifying said recovered infectious viral particles. Suitable host cells for production of the oncolytic virus include without limitation human cell lines such as HeLa (ATCC), 293 cells (Graham et al., 1997, J. Gen. Virol. 36: 59-72), HER96, PER-C6 (Fallaux et al., 1998, Human Gene Ther. 9: 1909-17), avian cells such as those described in WO2005/042728, WO2006/108846, WO2008/129058, WO2010/130756, WO2012/001075, etc), hamster cell lines such as BHK-21 (ATCC CCL-10) as well as primary chicken embryo fibroblasts (CEF) prepared from chicken embryos obtained from fertilized eggs. The oncolytic virus can be at least partially isolated before being used according to the present invention and disclosure. Various purification steps can be envisaged, including clarification, enzymatic treatment (e.g. benzonase, protease), chromatographic and filtration steps. Appropriate methods are described in the art (e.g. WO2007/147528; WO2008/138533, WO2009/100521, WO2010/130753, WO2013/022764).

Production of immune checkpoint modulator

[0100] The oncolytic virus may also be utilized for producing by recombinant means the one or more immune checkpoint modulator(s) that it encodes. It may advantageously comprise one or more additional element(s) enabling maintenance, propagation or expression of the nucleic acid molecule encoding the immune checkpoint modulator in a host cell. Such additional elements comprise marker gene(s) in order to facilitate identification and isolation of the producer host cells (e.g. by complementation of a cell auxotrophy or by antibiotic resistance). Suitable marker genes include without limitation dihydrofolate reductase (dhfr) which confers resistance to methotrexate (Wigler et al., 1980, Proc. Natl. Acad. Sci. USA 77: 3567; O'Hare et al., 1981, Proc. Natl. Acad. Sci. USA 78: 1527); gpt which confers resistance to mycophenolic acid (Mulligan and Berg, 1981, Proc. Natl. Acad. Sci. USA 78: 2072); neo which confers resistance to the aminoglycoside G-418 (Colberre-Garapin et al., 1981, J. Mol. Biol. 150: 1); zeo which confers resistance to zeomycin, kana which confers resistance to kanamycin; hygro, which confers resistance to hygromycin (Santerre et al., 1984, Gene 30: 147). Recombinant viruses lacking a functional TK (e.g. resulting from insertion of the nucleic acid molecule encoding the immune checkpoint modulator into the TK locus) may be selected with media containing bromodeoxyuridine (BrdU). Indeed, TK-viruses are insensitive to the BrdU drug whereas the drug interferes with DNA synthesis in TK+ viruses. One may also rely on reporter luminescent or colorimetric systems, e.g. based on GFP (green fluorescent protein), luciferase and beta-galactosidase.

[0101] The methods for recombinantly producing the immune checkpoint modulator are conventional in the art. Typically such methods comprise (a) introducing the oncolytic virus described herein into a suitable producer cell to produce a transfected or infected producer cell, (b) culturing in-vitro said transfected or infected producer cell under conditions suitable for its growth, (c) recovering the one or more immune checkpoint modulator(s) from the cell culture, and (d) optionally, purifying the recovered immune checkpoint modulator(s). Producer cells are preferably human or non-human eukaryotic cells. Preferred producer cells include without limitation BHK-21 (baby hamster kidney), CV-1 (African monkey kidney cell line), COS (e.g. COS-7) cells, Chinese hamster ovary (CHO) cells, mouse NIH/3T3 cells, mouse NSO myeloma cells, HeLa cells, Vero cells, HEK293 cells and PERC.6 cells and avian cells (e.g. chicken, duck cells as described herein).

[0102] The producer cells can be cultured in conventional fermentation bioreactors, flasks, and petri plates. Culturing can be carried out at a temperature, pH and oxygen content appropriate for a given host cell. No attempts to describe in detail the various methods known for the production of proteins in eukaryotic cells will be made here. Production of the immune checkpoint modulator can be intracellular or preferably secreted outside the producer cell (e.g. in the culture medium).

[0103] The immune checkpoint modulator can then be purified by well-known purification methods. The conditions and technology used to purify a particular protein will depend on factors such as the expression conditions, net charge, molecular weight, hydrophobicity, hydrophilicity and will be apparent to those having skill in the art. Moreover, the level of purification will depend on the intended use. If necessary, especially when the immune checkpoint modulator is not secreted outside the producer cell or where it is not secreted completely, it can be recovered by standard lysis procedures, including freeze thaw, sonication, mechanical disruption, use of lysing agents and the like. If secreted, it can be recovered directly from the culture medium. Suitable purification techniques include without limitation ammonium sulfate precipitation, acid extraction, gel electrophoresis, filtration and chromatographic methods (e.g. reverse phase, size exclusion, ion exchange, affinity, phosphocellulose, hydrophobic-interaction or hydroxylapatite chromatography, etc). Desirably, the immune checkpoint modulator recombinantly produced for the oncolytic virus is at least partially purified in the sense that it is substantially free of other antibodies having different antigenic specificities and/or other cellular material. Further, the immune checkpoint modulator may be formulated according to the conditions conventionally used in the art (e.g. WO2009/073569).

Therapeutic use

[0104] The present invention also provides a pharmaceutical composition comprising an effective amount of the oncolytic virus of the invention and a pharmaceutical acceptable vehicle.

[0105] More generally, the present disclosure also provides a composition comprising a therapeutically effective amount of the oncolytic virus of the invention and disclosure, optionally with a pharmaceutically acceptable vehicle. Such compositions may be administered once or several times and via the same or different routes

[0106] A "therapeutically effective amount" corresponds to the amount of oncolytic virus that is sufficient for producing one or more beneficial results. Such a therapeutically effective amount may vary as a function of various parameters, in particular the mode of administration; the disease state; the age and weight of the subject; the ability of the subject to respond to the treatment; kind of concurrent treatment; the frequency of treatment; and/or the need for prevention or therapy. When prophylactic use is concerned, the oncolytic virus or the composition of the invention and disclosure is administered at a dose sufficient to prevent or to delay the onset and/or establishment and/or relapse of a pathologic

condition (e.g. a proliferative disease such as cancer), especially in a subject at risk. For "therapeutic" use, the oncolytic virus or the composition of the present invention and disclosure is administered to a subject diagnosed as having a pathological condition (e.g. a proliferative disease such as cancer) with the goal of treating the disease, eventually in association with one or more conventional therapeutic modalities. In particular, a therapeutically effective amount could be that amount necessary to cause an observable improvement of the clinical status over the baseline status or over the expected status if not treated, e.g. reduction in the tumor number; reduction in the tumor size, reduction in the number or extend of metastasis, increase in the length of remission, stabilization (i.e. not worsening) of the state of disease, delay or slowing of disease progression or severity, amelioration or palliation of the disease state, prolonged survival, better response to the standard treatment, improvement of quality of life, reduced mortality, etc. A therapeutically effective amount could also be the amount necessary to cause the development of an effective non-specific (innate) and/or specific anti-tumor immune response. Typically, development of an immune response in particular T cell response can be evaluated *in vitro*, in suitable animal models or using biological samples collected from the subject. For example, techniques routinely used in laboratories (e.g. flow cytometry, histology) may be used to perform tumor surveillance. One may also use various available antibodies so as to identify different immune cell populations involved in anti-tumor response that are present in the treated subjects, such as cytotoxic T cells, activated cytotoxic T cells, natural killer cells and activated natural killer cells. An improvement of the clinical status can be easily assessed by any relevant clinical measurement typically used by physicians or other skilled healthcare staff.

[0107] The term "pharmaceutically acceptable vehicle" is intended to include any and all carriers, solvents, diluents, excipients, adjuvants, dispersion media, coatings, antibacterial and antifungal agents, absorption agents and the like compatible with administration in mammals and in particular human subjects.

[0108] The oncolytic virus or the composition thereof can be placed in a solvent or diluent appropriate for human or animal use. The solvent or diluent is preferably isotonic, hypotonic or weakly hypertonic and has a relatively low ionic strength. Representative examples include sterile water, physiological saline (e.g. sodium chloride), Ringer's solution, glucose, trehalose or saccharose solutions, Hank's solution, and other aqueous physiologically balanced salt solutions (see for example the most current edition of Remington : The Science and Practice of Pharmacy, A. Gennaro, Lippincott, Williams&Wilkins).

[0109] In one example, the oncolytic virus composition is suitably buffered for human use. Suitable buffers include without limitation phosphate buffer (e.g. PBS), bicarbonate buffer and/or Tris buffer capable of maintaining a physiological or slightly basic pH (e.g. from approximately pH 7 to approximately pH 9).

[0110] The oncolytic virus compositions may also contain other pharmaceutically acceptable excipients for providing desirable pharmaceutical or pharmacodynamic properties, including for example osmolarity, viscosity, clarity, color, sterility, stability, rate of dissolution of the formulation, modifying or maintaining release or absorption into the human or animal subject, promoting transport across the blood barrier or penetration in a particular organ.

[0111] The oncolytic virus compositions can also comprise one or more adjuvant(s) capable of stimulating immunity (especially a T cell-mediated immunity) or facilitating infection of tumor cells upon administration, e.g. through toll-like receptors (TLR) such as TLR-7, TLR-8 and TLR-9, including without limitation alum, mineral oil emulsion such as, Freund's complete and incomplete (IFA), lipopolysaccharide or a derivative thereof (Ribi et al., 1986, Immunology and Immunopharmacology of Bacterial Endotoxins, Plenum Publ. Corp., NY, p407-419), saponins such as QS21 (Sumino et al., 1998, J. Virol. 72: 4931; WO98/56415), imidazo-quinoline compounds such as Imiquimod (Suader, 2000, J. Am Acad Dermatol. 43:S6), S-27609 (Smorlesi, 2005, Gene Ther. 12: 1324) and related compounds such as those described in WO2007/147529, cytosine phosphate guanosine oligodeoxynucleotides such as CpG (Chu et al., 1997, J. Exp. Med. 186: 1623; Tritel et al., 2003, J. Immunol. 171: 2358) and cationic peptides such as IC-31 (Kritsch et al., 2005, J. Chromatogr Anal. Technol. Biomed. Life Sci. 822: 263-70).

[0112] The oncolytic virus composition of the present invention and disclosure may be formulated with the goal of improving its stability in particular under the conditions of manufacture and long-term storage (i.e. for at least 6 months, with a preference for at least two years) at freezing (e.g. -70°C, -20°C), refrigerated (e.g. 4°C) or ambient temperatures. Various virus formulations are available in the art either in frozen, liquid form or lyophilized form (e.g. WO98/02522, WO01/66137, WO03/053463, WO2007/056847 and WO2008/114021, etc). Solid (e.g. dry powdered or lyophilized) compositions can be obtained by a process involving vacuum drying and freeze-drying (see e.g. WO2014/053571). For illustrative purposes, buffered formulations including NaCl and sugar are particularly adapted to the preservation of viruses (e.g. Tris 10 mM pH 8 with saccharose 5 % (W/V), sodium glutamate 10 mM, and NaCl 50 mM or phosphate-buffered saline with glycerol (10%) and NaCl).

[0113] The oncolytic virus composition can be formulated to ensure proper distribution or a delayed release *in vivo*. For example, it can be formulated in liposomes. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Many methods for the preparation of such formulations are described by e.g. J. R. Robinson in "Sustained and Controlled Release Drug Delivery Systems", ed., Marcel Dekker, Inc., New York, 1978.

[0114] The appropriate dosage of oncolytic virus can be adapted as a function of various parameters and may be

routinely determined by a practitioner in the light of the relevant circumstances. Suitable dosage for the oncolytic virus varies from approximately 10^5 to approximately 10^{13} vp (viral particles), iu (infectious unit) or pfu (plaque-forming units) depending on the virus and the quantitative technique used. As a general guidance, vaccinia virus doses from approximately 10^5 to approximately 10^{13} pfu are suitable, preferably from approximately 10^6 pfu to approximately 10^{11} pfu, more preferably from approximately 10^7 pfu to approximately 5×10^9 pfu; doses of approximately 10^8 pfu to approximately 10^9 pfu being particularly preferred especially for human use. The quantity of virus present in a sample can be determined by routine titration techniques, e.g. by counting the number of plaques following infection of permissive cells using permissive cells (e.g. BHK-21 or CEF), immunostaining (e.g. using anti-virus antibodies; Carroll et al., 1997, Virology 238: 198-211), by measuring the A260 absorbance (vp titers), or still by quantitative immunofluorescence (iu titers).

[0115] Preferably, the administration(s) of said oncolytic virus composition permits to deliver at least 50ng/ml in a body sample obtained from the subject. In one embodiment, said level of immune checkpoint is obtained after a single administration of approximately 10^7 pfu to approximately 5×10^9 pfu of the oncolytic virus described herein and can be further increased with subsequent administration(s). In another example, the body sample is blood, serum, plasma, tumor biopsy, tumor homogenate, tumor fluid, etc and is collected at least one hour to one month after said administration(s). More preferably, *in situ* production of the encoded immune checkpoint modulator reached at least 100ng (e.g., at least 200ng/ml, at least 400ng/ml, at least 500ng/ml, at least 700 ng/ml, at least 800ng/ml, at least 900ng/ml, at least 1000ng/ml, at least 1200ng/ml, at least 1500ng/ml, at least 1800ng/ml, at least 2000ng/ml, at least at least 2500ng/ml and at least 3000ng/ml) per ml of said biological sample collected from the subject 2 to 8 days (e.g. 3 to 7 days or more preferably about 5 days) following the administration of said oncolytic virus. The levels of immune checkpoint inhibitor secreted *in situ* can be evaluated as described in the Examples.

Administration

[0116] The oncolytic virus or the composition of the present invention and disclosure may be administered in a single dose (e.g. bolus injection) or multiple doses. If multiple administrations, they may be performed by the same or different routes and may take place at the same site or at alternative sites. It is also possible to proceed via sequential cycles of administrations that are repeated after a rest period. Intervals between each administration can be from several hours to one year (e.g. 24h, 48h, 72h, weekly, every two weeks, monthly or yearly). Intervals can also be irregular (e.g. following tumor progression). The doses can vary for each administration within the range described above.

[0117] Any of the conventional administration routes are applicable in the context of the invention and disclosure including parenteral, topical or mucosal routes. Parenteral routes are intended for administration as an injection or infusion. Common parenteral injection types are intravenous (into a vein), intra-arterial (into an artery), intradermal (into the dermis), subcutaneous (under the skin), intramuscular (into muscle) and intratumoral (into tumor or at its close proximity). Infusions typically are given by intravenous route. Mucosal administrations include without limitation oral/alimentary, intranasal, intratracheal, intrapulmonary, intravaginal or intra-rectal route. Topical administration can also be performed using transdermal means (e.g. patch and the like). Administrations may use conventional syringes and needles (e.g. Quadrafuse injection needles) or any compound or device available in the art capable of facilitating or improving delivery of the active agent(s) in the subject. Preferred routes of administration for the oncolytic virus include intravenous and intratumoral routes.

[0118] In the context of the invention and disclosure, the oncolytic virus may be administered once or several time (e.g. 2, 3, 4, 5, 6, 7 or 8 times etc) at a dose within the range of from 10^7 to 5×10^9 pfu. The time interval between each administration can vary from approximately 1 day to approximately 8 weeks, advantageously from approximately 2 days to approximately 6 weeks, preferably from approximately 3 days to approximately 4 weeks and even more preferably from approximately 1 week to approximately 3 weeks (e.g. every two weeks for example). A preferred therapeutic scheme involves from 2 to 5 (e.g. 3) intravenous or intratumoral administrations of 10^8 or 10^9 pfu of oncolytic vaccinia virus at approximately 1 or 2 weeks interval.

[0119] The present invention also relates to a pharmaceutical composition comprising an effective amount of the oncolytic virus of the invention and a pharmaceutical acceptable vehicle for use for treating a proliferative disease, preferably a cancer. The present disclosure also relates to a method for treating a proliferative disease such as cancer comprising administering an oncolytic virus as described herein to a subject in need thereof.

[0120] The present disclosure also relates to a method for inhibiting tumor cell growth *in vivo* comprising administering an oncolytic virus as described herein to a subject in need thereof.

[0121] The present disclosure also relates to a method for enhancing an immune response to tumor cells comprising administering an oncolytic virus as described herein to a subject in need thereof.

[0122] In one example, the administration of the oncolytic virus for use in the present invention and disclosure elicits, stimulates and/or re-orientates an immune response. In particular, the administration induces a protective T or B cell response in the treated host, e.g. against said oncolytic virus or eventually against the product encoded by the therapeutic gene(s) inserted in the viral genome if any. The protective T response can be CD4+ or CD8+ or both CD4+ and CD8+ cell

mediated. B cell response can be measured by ELISA and T cell response can be evaluated by conventional ELISpot, ICS assays from any sample (e.g. blood, organs, tumors, etc) collected from the immunized animal or subject.

[0123] In one example, the administration of the oncolytic virus permits to change tumor microenvironment with the goal of enhancing activity of effector cells in the tumor, especially effector T lymphocytes and/or promoting at least partial Treg depletion. Tumor infiltrating cells can be easily identified for examples by conventional immunostaining assays.

[0124] In one example, the method herein disclosed and the oncolytic virus or composition of the invention provides a higher therapeutic efficacy than the one obtained in the same conditions with a similar oncolytic virus (without immune checkpoint modulator) or the immune checkpoint modulator either individually or even in co-administration. In the context of the invention and disclosure, the method herein disclosed and the oncolytic virus or composition of the invention provides at least 5%, at least 10%, at least 15%, at least 20%, or at least 25% more therapeutic efficacy than either the virus or the immune check point modulator alone or in co-administration. A higher therapeutic efficacy could be evidenced as described above in connection with the term "therapeutically effective amount" with a specific preference for a longer survival.

[0125] Examples of proliferative diseases that may be treated using the oncolytic virus and composition of the invention and disclosure, or methods herein disclosed, include bone cancer, liver cancer, pancreatic cancer, stomach cancer, colon cancer, cancer of the esophagus, oropharyngeal cancer, lung cancer, cancer of the head or neck, skin cancer, melanoma, uterine cancer, cervix cancer, ovarian cancer, breast cancer, rectal cancer, cancer of the anal region, prostate cancer, lymphoma, cancer of the endocrine system, cancer of the thyroid gland, sarcoma of soft tissue, chronic or acute leukemias, cancer of the bladder, renal cancer, neoplasm of the central nervous system (CNS), glioma, etc. The present invention and disclosure is also useful for treatment of metastatic cancers, especially metastatic cancers that express PD-L1 (Iwai et al., 2005, Int. Immunol. 17: 133-44). Preferred cancers that may be treated using the oncolytic virus of the invention and disclosure include cancers typically responsive to immunotherapy. Non-limiting examples of preferred cancers for treatment include melanoma (e.g. metastatic malignant melanoma), renal cancer (e.g. clear cell carcinoma), prostate cancer (e.g. hormone refractory prostate adenocarcinoma), breast cancer, colorectal cancer, lung cancer (e.g. non-small cell lung cancer) and liver cancer (e.g. hepatocarcinoma).

[0126] According to an advantageous example, especially when the oncolytic virus is armed with a suicide gene, the oncolytic virus therapy of the invention and disclosure or methods disclosed herein may comprise an additional step in which pharmaceutically acceptable quantities of a prodrug, advantageously an analog of cytosine, in particular 5-FC, are administered to the subject. By way of illustration, it is possible to use a dose of from 50 to 500 mg/kg/day, with a dose of 200 mg/kg/day or of 100 mg/kg/day being preferred. Within the context of the present invention and disclosure, the prodrug is administered in accordance with standard practice (e.g. per os, systematically, etc). Preferably, the administration taking place subsequent to the administration of the oncolytic virus, preferably at least 3 days, more preferably at least 4 days and even more preferably at least 7 days after the administration of the virus. The oral route is preferred. It is possible to administer a single dose of prodrug or doses which are repeated for a time which is sufficiently long to enable the toxic metabolite to be produced within the host organism or cell.

[0127] The oncolytic virus and composition of the invention and disclosure or method herein disclosed can be associated with one or more substances or therapy effective in anticancer therapy and the present disclosure also concerns a method which comprises the step of delivering to the subject an additional cancer therapy. In the context of the present invention and disclosure, said additional cancer therapy comprises surgery, radiation, chemotherapy, immunotherapy, hormone therapy or a combination thereof. Preferably, the method disclosed herein comprises the administration of one or more substances effective in anticancer therapy. Among pharmaceutical substances effective in anticancer therapy which may be used in association or in combination with the oncolytic virus and composition of the invention and disclosure or method disclosed herein, there may be mentioned more specifically:

- ✓ alkylating agents such as e.g. mitomycin C, cyclophosphamide, busulfan, ifosfamide, isosfamide, melphalan, hexamethylmelamine, thiotepa, chlorambucil, or dacarbazine;
- ✓ antimetabolites such as, e.g. gemcitabine, capecitabine, 5-fluorouracil, cytarabine, 2-fluorodeoxy cytidine, methotrexate, idatrexate, tomudex or trimetrexate;
- ✓ topoisomerase II inhibitors such as, e.g. doxorubicin, epirubicin, etoposide, teniposide or mitoxantrone;
- ✓ topoisomerase I inhibitors such as, e.g. irinotecan (CPT-11), 7-ethyl-10-hydroxy-camptothecin (SN-38) or topotecan;
- ✓ antimitotic drugs such as, e.g., paclitaxel, docetaxel, vinblastine, vincristine or vinorelbine;
- ✓ platinum derivatives such as, e.g., cisplatin, oxaliplatin, spiroplatinum or carboplatinum;
- ✓ inhibitors of tyrosine kinase receptors such as sunitinib (Pfizer) and sorafenib (Bayer);
- ✓ anti-neoplastic antibodies in particular antibodies that affect the regulation of cell surface receptors such as trastuzumab, cetuximab, panitumumab, zalutumumab, nimotuzumab, matuzumab, bevacizumab and ranibizumab;
- ✓ EGFR (for Epidermal Growth Factor Receptor) inhibitors such as gefitinib, erlotinib and lapatinib; and
- ✓ immunomodulatory agents such as, e.g. alpha, beta or gamma interferon, interleukin (in particular IL-2, IL-6, IL-

10 or IL-12) or tumor necrosis factor;

[0128] The oncolytic virus and composition of the invention and disclosure or method disclosed herein can also be used in association with radiotherapy.

[0129] The present disclosure also provides kits including a different container (e.g., a sterile glass or plastic vial) for each virus dose to be administered. Optionally, the kit can include a device for performing the administration of the active agents. The kit can also include a package insert including information concerning the compositions or individual component and dosage forms in the kit.

Brief Description of the Drawings

[0130]

Figure 1 illustrates the quantity of purified anti-PD-1 mAb, Fab and scFv produced from infected CEF.

Figure 2 illustrates an analysis by electrophoresis of the purified recombinant mAb (Vacc.mAb) and scFv (Vacc.scFv) as well as commercial J43 (BioXCell) under reduced (R) and non reduced (NR) conditions.

Figure 3: *In vitro* replication efficacy of viruses in LoVo infected at a MOI of 0.0001, 0.001 and 0.01 with the indicated viruses at day 5 post infection. Values are represented in mean $\pm$ SD of three individual determinations.

Figure 4 illustrates the amino acid sequences of the heavy and light chains of the anti-PD1 antibodies expressed by the oncolytic vaccinia virus described herein.

Figure 5 illustrates immunoblot analysis of the recombinant mAb and Fab secreted in cell culture supernatants obtained from CEF infected with WRTG18618, WRTG18619, WRTG18620 and WRTG18621. Commercial J43 is used as reference; M represents MW markers and C negative control.

Figure 6 illustrates the concentration of recombinant J43 produced in the serum (Figure 6A) and in tumor homogenate (Figure 6B) of mice treated with a single administration of WRTG18618 (10^7 pfu) injected intratumorally (resulting from subcutaneous implantation of B16F10 tumors) or subcutaneously (mice without tumors) or with intratumoral administration of $1\mu\text{g}$ or $10\mu\text{g}$ of commercial J43 (BioXcell). Concentration of recombinant J43 was measured by quantitative ELISA 1, 5 and 11 days after injection.

Examples

[0131] These examples illustrate oncolytic vaccinia virus engineered for expressing various forms of anti-immune checkpoint inhibitors. Preclinical evidence for the beneficial effects of expressing immune checkpoint blockers from viral vectors was to be demonstrated in mouse tumor models. This implies the use of i) murine-specific anti-immune checkpoint antibodies and ii) an oncolytic poxvirus capable of infecting murine cells with a higher efficacy.

[0132] The murine-specific hamster antibody J43 was chosen to target the immune checkpoint blocker murine PD-1 (mPD-1). This antibody was shown to block the interaction of mPD1 with PD-L1 (US patent 7,858,746). The antibody J43 and its isotype control (hamster IgG) are available from BioXCell. The anti mPD-1 antibodies and its isotype control were used to establish functional tests and quantitative ELISA *in vitro*. Further, J43 and various forms thereof were cloned in an oncolytic virus and tested *in vivo* in tumor animal models.

[0133] The oncolytic virus chosen for these studies is a vaccinia virus (VV) Western Reserve (WR) strain defective for thymidine kinase (TK^-) (locus J2R) and RR^- (locus I4L) rendering the virus non-replicative in healthy (non-dividing) cells. In contrast, the VV $\text{TK}^- \text{RR}^-$ is supposed to selectively and efficiently replicate in tumor cells.

Vectorization of anti mPD-1 molecules in oncolytic $\text{TK}^- \text{RR}^-$ vaccinia virus.

[0134] The heavy chain of J43 showed high homology with the heavy chain of anti CD79b IgG. Thus, the sequence retained for cloning of the heavy chain was the variable chain of J43 and the constant chain of anti CD79b. The light chain of J43 was cloned with signal sequence from the light chain of anti CD79b antibody. The heavy and light chains were put under the control of the viral promoters pH5R or p7.5K which have slightly different strengths. Further to "whole" antibody constructs, derivatives were generated, respectively His-tagged antigen binding fragments (Fab) constructs as well as a His-tagged single chain antibody (scFv) constructs. Two construct formats were also generated for Fab depending on the light or heavy chain portions placed under each promoter. All five constructs were inserted in the backbone of $\text{TK}^- \text{RR}^-$ WR VV. The constructs are summarized below:

WRTG18618 (or mAb1) corresponding to pH5R-HC - p7.5K-LC

WRTG18619 (or mAb2) corresponding to pH5R-LC - p7.5K-HC

WRTG18621 (or Fab1) corresponding to pH5R-(VH-CH1-6His) - p7.5K-LC

EP 3 169 341 B1

WRTG18620 (or Fab2) corresponding to pH5R-LC - p7.5K-(VH-CH1-6His)

WRTG18616 (scFv) corresponding to pH5R-VH-gs-VL-6His).

[0135] HC and LC represent the abbreviation of heavy and light chains, VH and VL of heavy and light variable domains, 6His of the HIS tag (6 histidines) and gs (poly Glycine-Serine linker)

[0136] Constructs 1 demonstrated the highest expression level of the recombinant mAb or Fab with the expected chain assembly profiles.

[0137] Virus stocks WRTG18616 (scFv), WRTG18618 (mAb1) and WRTG18621 (Fab1) were produced in BHK-21 cells and purified by tangential flow filtration (TFF).

Construction of WRTG18618 (pH5R-HC-p7.5K-LC): mAb1

[0138] Fragment containing HC followed by p7.5K promoter was generated by synthetic way (Geneart: Regensburg, Germany) and was cloned in vaccinia transfer plasmid pTG18496 restricted by *Pst*I and *Eco*RI to give pTG18614. Fragment containing LC was generated by synthetic way and was cloned in pTG18614 restricted by *Nsi*I and *Sa*I to give pTG18618.

[0139] The vaccinia transfer plasmid, pTG18496, is designed to permit insertion of the nucleotide sequence to be transferred by homologous recombination in TK gene of the VV genome. It contains the flanking sequences (BRGTK and BRDTK) surrounding the J2R gene and the pH5R promoter followed by multiple cloning sites.

[0140] The amino acid sequences of the anti-PD-1 HC and LC are given in SEQ ID NO: 1 and SEQ ID NO: 2, respectively and in Figure 4.

[0141] Generation of WRTG18618 was performed by homologous recombination in primary chicken embryos fibroblasts (CEF) infected with a RR-deleted WR and transfected by nucleofection with pTG18618 (according to Amaxa Nucleofector technology). Viral selection was performed by plaque purification after growth in Thymidine kinase-deficient (TK⁻) 143B cells cultured in the presence of bromodeoxyuridine. This selection allows only TK⁻ rWR to remain viable. Absence of contamination by parental WR was verified by PCR.

Construction of WRTG18619 (pH5R-LC-p7.5K-HC): mAb2

[0142] Fragment containing LC followed by p7.5K promoter was generated by synthetic way and was cloned in vaccinia transfer plasmid pTG18496 restricted by *Pst*I and *Eco*RI to give pTG18615. Fragment containing HC was generated by synthetic way and was cloned in pTG18615 restricted by *Nsi*I and *Mlu*I to give pTG18619.

[0143] Generation of WRTG18619 virus was performed in CEF by homologous recombination as described above.

Construction of WRTG18621 (pH5R-(VH-CH1-6His) - p7.5K-LC): Fab1

[0144] Fragment containing VH-CH1-6His followed by p7.5K promoter was generated by synthetic way and was cloned in vaccinia transfer plasmid pTG18496 restricted by *Pst*I and *Eco*RI to give pTG18617. Fragment containing LC was generated by synthetic way and was cloned in pTG18617 restricted by *Nsi*I and *Sa*I to give pTG18621.

[0145] Generation of WRTG18621 virus was performed in CEF by homologous recombination as described above.

Construction of WRTG18620 (pH5R-LC-p7.5K-(VH-CH1-6His): Fab2

[0146] Fragment containing LC followed by p7.5K promoter was generated by synthetic way and was cloned in vaccinia transfer plasmid pTG18496 restricted by *Pst*I and *Eco*RI to give pTG18615. Fragment containing VH-CH1-6His was generated by synthetic way and was cloned in pTG18615 restricted by *Nsi*I and *Mlu*I to give pTG18620.

[0147] Generation of WRTG18620 virus was performed in CEF by homologous recombination as described above.

Construction of WRTG18616 (pH5R-VH-gs-VL-6His): scFv

[0148] Fragment containing VH-gs-VL-6His was generated by synthetic way and was cloned in vaccinia transfer plasmid pTG18496 restricted by *Pst*I and *Eco*RI to give pTG18616.

[0149] Generation of WRTG18616 virus was performed in CEF by homologous recombination as described above.

In vitro characterization of the encoded anti-PD-1 antibodies

[0150] The recombinant oncolytic vectors described above were tested to assess the production of the encoded anti-mPD-1 molecules. To this, permissive primary cells or cell lines were infected, and supernatant harvested. Presence of

anti-mPD-1 molecules can be determined by SDS-PAGE, Western blot analysis, mass spectrometry analysis, ELISA and functional assays. Commercially available anti-mPD-1 antibodies were used as controls.

[0151] Supernatant from infected CEF (moi 0.2) were analyzed (after 48 and 72 h post infection) by Western Blot under non-reducing conditions using a polyclonal anti-hamster IgG antibody for detection. WRTG18618 (mAb1) and WRTG18621 (Fab1) could be detected by ELISA. Expression profile of the product secreted by WRTG18618-infected cells has similar pattern as commercial J43 antibody and expected assembly of the product secreted by WRTG18621-infected cells was observed. ScFv expression was also detected in culture supernatant by Western Blot at the expected size.

mAb purification and In vitro assessment of anti PD-1 antibodies

[0152] CEF were cultured in F175 flasks and infected with 2.7×10^8 pfu of anti-PD-1-expressing viruses. After 48-72h, culture supernatants were collected and subjected to filtration on $0.2 \mu\text{m}$ filters. mAb1 was purified by Hitrap protein A (GE Healthcare) followed by Superdex 200 gel filtration (GE Healthcare) whereas Fab1 and scFv were purified by HIS-Trap (GE Healthcare) followed by Superdex 75 gel filtration (GE Healthcare). scFv eluted from gel filtration in two peaks, the first one corresponding to dimers and the second one to monomers. Significant amounts of mAbs, Fab and scFv were produced as shown in Figure 1. The yield is between 0,5 and 2 $\mu\text{g/ml}$ supernatant according to the antibody format.

[0153] Recombinant purified mAb had an electrophoresis profile similar to the commercial mAbs with the correct assembly of the two light and two heavy chains under non reducing conditions and the detection of the individual light and heavy chains under reducing conditions as illustrated in Figure 2. Moreover, purified scFv migrated on SDS-PAGE at the expected size (see Figure 2).

[0154] The recombinant products can be detected by ELISA and are functional in a competition ELISA (i.e. blocking of binding of mouse PD-L1 biot at $0.2 \mu\text{g/ml}$ to mouse PD-1 coated at $1 \mu\text{g/ml}$), mAb being more efficient than Fab in this competition experiment. Moreover, the recombinant mAb1 is more efficient than its commercial J43 counterpart as well as VV-produced scFv dimeric fraction is more efficient than the monomeric one with a difference of approximately one log in EC_{50} .

[0155] The ability of VV-encoded mAb1, Fab1 and scFv to interact with cell-surface PD-1 was studied in flow cytometry-based binding assays using the PD-1-positive T lymphoma cell lines EL4 and RMA. 10^5 EL4 or RMA cells were incubated for 45 min on ice with 100 μl of either mAb1 (5 $\mu\text{g/ml}$), commercially available anti-mPD-1 antibody J43 (5 $\mu\text{g/ml}$, BioXCell) or negative control hamster IgG (5 $\mu\text{g/ml}$, BioXCell) and washed. Binding to PD-1 was detected by incubating cells for 45 min on ice with 100 μl of 10 $\mu\text{g/ml}$ FITC-conjugated monoclonal mouse anti-Armenian + Syrian antibody cocktail (BD Pharmingen). After washing, fluorescence intensity was measured on a Navios™ flow cytometer (Beckman Coulter). Data were analysed using Kaluza 1.2 software (Beckman Coulter). WRTG18618-encoded mAb1 bound efficiently to EL4 and RMA cells.

[0156] To measure the binding of Fab1 and scFv, 5×10^5 EL4 or RMA cells were indirectly stained with either 5 $\mu\text{g/ml}$ Fab1 or 2.5 $\mu\text{g/ml}$ monomeric scFv (which are both His-tagged) followed by PE-conjugated monoclonal mouse anti-His tag antibody (diluted 1/10, Miltenyi Biotec) and analysed as described above. Fab1 and monomeric scFv produced from WRTG18621 and WRTG18616 were shown to bind efficiently to the surface of EL4 and RMA cells. Specific binding could be demonstrated by co-incubating EL4 cells with Fab1 or monomeric scFv and full-length J43 or negative control hamster IgG from BioXCell, followed by staining with PE-conjugated anti-His tag antibody. EL4 staining was reduced in the presence of full-length J43 but not negative control hamster IgG. Altogether, the results demonstrated that VV-encoded mAb1, Fab1 and scFv were able to recognize endogenously expressed PD-1 in two murine T lymphocyte cell lines.

[0157] A flow cytometry-based competition assay was established to compare blocking activity of anti-mPD-1 molecules. The assay is based on the murine T lymphoma cell line EL4 which is highly PD-1 positive. The binding of mPD-L1-hFc (murine PD-Ligand 1 comprising human IgG Fc fragment) to the cell-surface PD1 can be detected by flow cytometry using a PE-labeled anti-hFc monoclonal antibody. Binding of mPD-L1-hFc can be competed for by anti-PD-1 antibodies leading to reduction of cell-bound PE signal.

[0158] The inhibitory activity of recombinant mAb1, Fab1 and scFv on PD-L1 binding to EL4 cells was assessed and compared to commercially available J43 anti-PD-1 antibody (BioXCell). More specifically, 10^5 EL4 cells were co-incubated with 2 $\mu\text{g/ml}$ of mPD-L1 hFc (R&D Systems) and increasing concentrations of the various anti-PD-1 antibodies in 100 μl for 45 min on ice. After washing, cells were incubated with 100 μl of 5 $\mu\text{g/ml}$ PE-conjugated mouse anti-human IgG Fc (BioLegend) for 45 min on ice. Cells were washed and the mean fluorescence intensity was measured as described above. In these conditions, the control anti mPD-1 clone J43 showed an IC_{50} of 1.6 $\mu\text{g/ml}$.

[0159] As expected, the control hamster IgG did not show any blocking activity on PD-L1 binding to EL4 cells. The recombinant mAb1, Fab1, monomeric and dimeric scFv produced respectively from WRTG18618, WRTG18621 and WRTG18616 were able to block ligand binding to cell-surface receptor as J43 from BioXCell. Importantly, WRTG18618-encoded mAb1 exhibited enhanced blocking activity as compared to J43 from BioXCell and Fab1 and scFv versions in

this assay.

[0160] A quantitative ELISA was established to quantify antibody concentrations produced in mouse serum or by recombinant WR-infected cells using coated rabbit-derived anti hamster antibodies to capture J43, which could be detected in return with a goat-derived anti hamster antibody. The assay is sensitive to mouse serum and standard curves have to be generated in the presence of 50% mouse serum..

***In vitro* cytotoxicity assay (oncolytic activity)**

[0161] Human LoVo colon cancer cell line was transduced in suspension at a MOI of 0.001 and 0.0001 by TK- RR deleted WR vaccinia virus without transgene (WRTG18011) and by TK-RR-deleted WR vaccinia virus expressing the different anti mPD-1 molecules (WRTG18616, WRTG18618 and WRTG8621). A total of 3×10^5 cells/well were plated in 6-well culture dishes in 2 ml of medium supplemented with 10 % FCS. Cells were then cultured at 37°C and cell survival was determined 5 days later by trypan blue exclusion. As shown in Figure 3, the oncolytic activity of the different viruses resulted in 75-95% and 99% reduction in viable cell number at a MOI of 0.0001 and 0.001, respectively. TK-RR-deleted WR virus without transgene and TK-RR deleted WR virus expressing the different anti mPD-1 molecules showed no difference in cytotoxicity. Thus the expression of the different anti mPD-1 molecules did not affect the oncolytic activity of the vaccinia virus.

Optimal design for antibody expression

[0162] The recombinant oncolytic vectors were tested by Immunoblotting to assess expression levels and assembly of the secreted antibodies. Immunoblot analyses were performed on cell culture supernatants collected 24h after CEF infection with mAb and Fab constructs described above. Supernatant were centrifuged 5 min at 16000 g and 25µl were prepared in Laemmli buffer without reducing agent and loaded on PrecastGel 4-15 % polyacrylamide gel (Biorad). Monoclonal commercial J43 (BioXcell) was used as reference molecule. One µg of each molecule was loaded on gel. Gel electrophoresis was performed in non-reducing conditions to preserve the assembly of light and heavy chains and allow an optimal detection (*i.e.* the polyclonal antibody used for detection did not recognized reduced IgG and Fab chains). Proteins were then transferred onto a PVDF membrane using the Trans-blot Turbo system (Transblot Turbo Transfer pack Biorad) with the preprogrammed protocol (High MW: 10 min; 2.5 A constant; up to 25V). Membranes were saturated overnight at 4°C in blocking solution (8mM NaPO₄, 2mM KPO₄, 154mM NaCl pH 7.2 (PBS) supplemented with 0.05 % Tween20, 5 % Nonfat dry milk Biorad). Horseradish peroxidase (HRP) conjugated goat anti Armenian Hamster IgG (Jackson Immunoresearch) at 80 ng/mL in dilution buffer (PBS, 0.05 % Tween20, 0.5 % Nonfat dry milk) was used for the antibody immunodetection. Development was performed with Amersham ECL Prime Western Blotting detection reagents and Molecular Imager ChemiDOC™ XRS was used to capture chemiluminescence.

[0163] As illustrated in Figure 5, both WRTG18618 and WRTG18619 secreted roughly the same quantities of an antibody product with an apparent size corresponding to two heavy and two light chains linked together comparable to that of commercial J43 mAb. However, WRTG18619 also produced a non-expected product migrating between 43 and 55 kDa markers (see the extra band indicated by an arrow in the fourth lane "18619"). Similarly, an extra band was also present in the WRTG18620-infected culture supernatant (same position and same intensity in the fifth lane "18620") whereas WRTG18621 produced high amount of correctly assembled Fab without any detectable misassembled product (see arrow head in the sixth lane "18621").

[0164] Analyses of cell culture supernatants generated after infection of mammal cell lines BHK21 and A549 generated the same profile (data not shown).

[0165] When looking at the construct design, it appears that in both WRTG18619 and WRTG18620 constructs, the antibody light chain was placed under the transcriptional control of pH5R promoter (a strong promoter). One hypothesis is that in this configuration, antibody light chains could be overexpressed with respect to heavy chains and thus can assemble in homodimers. Therefore, this extra band, migrating between 43 and 55 kDa, could correspond to overproduced light chains that have assembled into a homodimer of a theoretical mass of 47 kDa.

[0166] Therefore, it is preferable to express heavy chain under the control of a stronger promoter than the one used to express light chains in order to reduce the risk of generating aberrant assembly (e.g. homodimers of light chains)

[0167] All together these results confirmed the ability of the recombinant oncolytic viruses described herein to secrete mAb and Fab at detectable level. WRTG18618 and WRTG18621 were selected for the rest of experiments due to their capacity to produce antibody products that are closer to expectation than those of WRTG18619 and WRTG18620.

***In vivo* expression of vectorised anti-PD1 antibody**

[0168] Expression of the vectorized anti-PD-1 J43mAb was evaluated *in vivo* in mice with and without subcutaneously-implanted B16F10 tumors. WRTG18618 (mAb1 construct) was injected either intra-tumorally or subcutaneously and

compared to commercial J43 (intra-tumoral injection).

In vivo experiments and sample collection

[0169] More specifically, 3×10^5 B16F10 cells (murine melanoma) were injected subcutaneously (S.C.) into the right flanks of six weeks old female C57BL/6 mice. At day 0 (D0), when tumor volumes reached 100-200 mm³, 100 microliters of either WRTG18618 (10^7 pfu) or commercial J43 (1 µg or 10 µg, Bioxcell) were injected intra-tumorally (I.T.).

[0170] WRTG18618 was also injected S.C in mice without tumor.

[0171] Blood and tumors were collected at D1, D5 and D11. For each time point, 3 mice were anesthetized with 200 µL pentobarbital and the blood was collected by intra-cardiac puncture. The blood was stored at 4 °C during 8 hours and the serum was recovered after two centrifugations and kept at -20 °C until analysis. After blood sampling, mice were sacrificed by cervical elongation and the tumor recovered. Tumors were weighted, cut into small pieces and transferred in GentleMACS C-type tubes (Miltenyi) containing 3 ml PBS. Tumors were mechanically dissociated applying program "m-imp tumor01" (GentleMacs, Miltenyi). After centrifugation at 300g for 7 min, supernatants were recovered and kept at -20 °C until analysis.

[0172] J43 concentration was measured by quantitative ELISA both in serum and in tumor homogenates at different time points after virus or commercial J43 mAb injections.

Quantitative ELISA

[0173] J43 concentrations was evaluated both in serum and tumor homogenates. More specifically, ninety-six wells plates (Nunc immune plate Maxisorp) were incubated overnight at 4 °C with 100 µL/well of 0.8 µg/mL of goat anti-hamster IgG (Southern Biotech) in coating solution (0.05M Na carbonate pH 9.6, Sigma). Plates were washed three times with wash buffer (300 µL/well of PBS, 0.05 % Tween20) and incubated 1h at RT with 200 µL/well of blocking solution (PBS, 0.05% Tween 20, 5 % Non Fat Dry Milk). Plates were washed three times with washing buffer. A standard range of J43 (BioXcell) was prepared in 100 % mouse serum (Sigma) from 1000 to 0.488 ng/mL by 2 fold serial dilutions. Each standard was then further diluted 2 fold in blocking solution (final J43 concentration from 500 to 0.244 ng/mL) to have a final concentration of serum of 50%. One hundred µL/well of each standard were added in duplicate on the plate. Samples of serum were diluted at least two fold in blocking buffer, and if necessary further diluted in 1Vol/1Vol mix of blocking buffer/serum and 100 µL were added to the plates. The plates were incubated 2h at 37 °C. After 3 washes with wash buffer, 100 µL/well of HRP conjugated goat anti Armenian Hamster IgG (Jackson ImmunoResearch) at 80 ng/mL were added and plates were incubated 1h at 37 °C. After 3 washes, 100 µL/well of 3,3',5,5'-tétraméthylbenzidine (TMB, Sigma) were added and the plates incubated at RT for 30 min. The reaction was stopped with 100 µL/well of 2M H₂SO₄ and the absorbance was measured at 450 nm with a plate reader (TECAN Infinite M200 PRO). The OD values obtained were transferred to the software GraphPadPrism and samples concentrations were back-calculated using the standard curve fitted with 5 parameters.

[0174] As shown in Figure 6A, when injected subcutaneously in a naive mice (no tumors implanted), production of recombinant J43 from WRTG18618 was very weak (9ng/ml at day 1 and 4.5ng/ml at day 5). In contrast, high quantities of recombinant J43 were secreted in serum of mice bearing B16F10 tumors following intratumoral WRTG18618 injection, respectively 9 and 1900 times higher at D1 and D5 (83 ng/ml and 9500 ng/ml) than the concentration of recombinant J43 measured after subcutaneous virus injection. This result suggests that the oncolytic virus is multiplying preferentially in tumors rather than in subcutaneous healthy tissues. In comparison, seric concentrations found after intratumoral injection of 10 µg commercial J43 reached around 1000ng/ml (1306 ng/ml at D1 and 1049ng/ml at D5) whereas the seric concentrations were much lower with 1 µg of commercial J43 (73ng/ml at D1 and 35ng/ml at D5).

[0175] In tumor homogenates, the production of recombinant J43 followed the same trend as in serum with a peak of concentration at D5 (see Figure 6B). The pharmacokinetics of J43 after a single IT injection of commercial mAb or WRTG18618 are very different. Following IT injection of 10 µg of commercial J43, the maximum antibody concentration was measured in serum and in tumor at D1 (1306ng/ml and 173ng/ml respectively) as expected, whereas IT injection of WRTG18618 resulted in maximum seric and tumor concentrations at D5 (9500ng/ml and 3800ng/ml, respectively). It should be highlighted that tumor concentrations of recombinant J43 produced after virus IT injection were much higher than those measured after IT injection of 10 µg commercial J43 at all time points (410ng/ml versus 173ng/ml at D1; 3800ng/ml versus 51ng/ml at D5 and 700ng/ml versus under detection limit at D11). Importantly, antibody production was still detected in tumors at D11 after virus treatment, which is not the case after commercial J43 injection.

[0176] These data suggest that vectorization of J43 in oncolytic viruses allow a higher and longer accumulation of antibody in tumors compared to IT injection of commercial antibody.

Antitumor activity in subcutaneous tumor model

[0177] Antitumor activity of the various anti-PD-1-expressing vaccinia viruses described above may be tested in conventional preclinical models after implantation of tumors followed by injection of the constructs. For example, murine cancer cells are injected subcutaneously into the flanks of immunocompetent mice. When tumors reached a volume of 50-70 mm³, the mice are randomized in a blinded manner and treated with the indicated vaccinia virus at a dose of 1x10⁷ PFU. The vectors or control vehicle (buffer used to resuspend the virus) are directly injected into the tumor at days 10, 12 and 14 after tumor implantation. Tumor size is measured twice weekly using calipers. In particular, vectorised scFv and mAb1 antibody are at least as efficient as the co-administration of a WR vector with commercial J43 to delay tumor growth and increase survival rate.

[0178] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific method and reagents described herein, including alternatives, variants, additions, deletions, modifications and substitutions. Such equivalents are considered to be within the scope of this disclosure

SEQUENCE LISTING**[0179]**

<110> Transgene SA SILVESTRE, Nathalie GEIST, Michel RITTNER, Karola MARCHAND, Jean-Baptiste THIOUDELLET, Christine

<120> Oncolytic virus for expression of immune checkpoint modulators

<130> B368022D35114

<150> EP14306153.9

<151> 2014-07-16

<160> 2

<170> PatentIn version 3.5

<210> 1

<211> 478

<212> PRT

<213> artificial sequence

<220>

<223> amino acid sequence for anti PD-1 heavy chain

<400> 1

EP 3 169 341 B1

Met	Gly	Leu	Gly	Leu	Gln	Trp	Val	Phe	Phe	Val	Ala	Leu	Leu	Lys	Gly
1				5					10					15	
5															
Val	His	Cys	Glu	Val	Arg	Leu	Leu	Glu	Ser	Gly	Gly	Gly	Leu	Val	Lys
			20					25					30		
10															
Pro	Glu	Gly	Ser	Leu	Lys	Leu	Ser	Cys	Val	Ala	Ser	Gly	Phe	Thr	Phe
		35					40					45			
15															
Ser	Asp	Tyr	Phe	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu
	50					55					60				
20															
Glu	Trp	Val	Ala	His	Ile	Tyr	Thr	Lys	Ser	Tyr	Asn	Tyr	Ala	Thr	Tyr
65					70					75					80
25															
Tyr	Ser	Gly	Ser	Val	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asp	Ser
				85					90					95	
30															
Ala	Thr	Tyr	Tyr	Cys	Thr	Arg	Asp	Gly	Ser	Gly	Tyr	Pro	Ser	Leu	Asp
		115					120					125			
35															
Phe	Trp	Gly	Gln	Gly	Thr	Gln	Val	Thr	Val	Ser	Ser	Ala	Thr	Thr	Thr
40															
45															
50															
55															

EP 3 169 341 B1

	130		135		140											
5	Ala	Pro	Ser	Val	Tyr	Pro	Leu	Ala	Pro	Ala	Cys	Asp	Ser	Thr	Thr	Ser
	145					150					155					160
	Thr	Thr	Asp	Thr	Val	Thr	Leu	Gly	Cys	Leu	Val	Lys	Gly	Tyr	Phe	Pro
					165					170					175	
10	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val
				180					185					190		
15	His	Thr	Phe	Pro	Ser	Val	Leu	His	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser
			195					200					205			
20	Ser	Val	Thr	Val	Pro	Ser	Ser	Thr	Trp	Pro	Lys	Gln	Pro	Ile	Thr	Cys
	210						215					220				
25	Asn	Val	Ala	His	Pro	Ala	Ser	Ser	Thr	Lys	Val	Asp	Lys	Lys	Ile	Glu
	225					230					235					240
30	Pro	Arg	Thr	Asp	Thr	Asp	Thr	Cys	Pro	Asn	Pro	Pro	Asp	Pro	Cys	Pro
					245					250					255	
35	Thr	Cys	Pro	Thr	Pro	Asp	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Ile	Phe
				260					265					270		
40	Pro	Pro	Lys	Pro	Lys	Asp	Val	Leu	Met	Ile	Ser	Leu	Thr	Pro	Lys	Ile
			275					280					285			
45	Thr	Cys	Val	Val	Val	Asp	Val	Ser	Glu	Glu	Glu	Pro	Asp	Val	Gln	Phe
	290						295					300				
50	Asn	Trp	Tyr	Val	Asn	Asn	Val	Glu	Asp	Lys	Thr	Ala	Gln	Thr	Glu	Thr
	305					310					315					320
55	Arg	Gln	Arg	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Pro
					325					330					335	
60	Ile	Lys	His	Gln	Asp	Trp	Met	Ser	Gly	Lys	Val	Phe	Lys	Cys	Lys	Val
				340					345					350		
65	Asn	Asn	Asn	Ala	Leu	Pro	Ser	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Pro
			355					360					365			
70	Arg	Gly	Gln	Val	Arg	Val	Pro	Gln	Ile	Tyr	Thr	Phe	Pro	Pro	Pro	Ile
	370						375					380				

EP 3 169 341 B1

	Glu	Gln	Thr	Val	Lys	Lys	Asp	Val	Ser	Val	Thr	Cys	Leu	Val	Thr	Gly	385	390	395	400
5	Phe	Leu	Pro	Gln	Asp	Ile	His	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	405	410	415	
10	Gln	Pro	Glu	Gln	Asn	Tyr	Lys	Asn	Thr	Gln	Pro	Val	Leu	Asp	Ser	Asp	420	425	430	
15	Gly	Ser	Tyr	Phe	Leu	Tyr	Ser	Lys	Leu	Asn	Val	Pro	Lys	Ser	Arg	Trp	435	440	445	
20	Asp	Gln	Gly	Asp	Ser	Phe	Thr	Cys	Ser	Val	Ile	His	Glu	Ala	Leu	His	450	455	460	
25	Asn	His	His	Met	Thr	Lys	Thr	Ile	Ser	Arg	Ser	Leu	Gly	Asn	465	470	475			
30	<210> 2																			
	<211> 233																			
	<212> PRT																			
	<213> artificial sequence																			
	<220>																			
	<223> amino acid sequence for anti PD1 light chain																			
35	<400> 2																			
40																				
45																				
50																				
55																				

EP 3 169 341 B1

	Met	Ala	Trp	Thr	Pro	Gly	Ile	Phe	Met	Val	Leu	Ser	Tyr	Leu	Thr	Gly
	1				5					10					15	
5	Ser	Phe	Ser	Tyr	Glu	Leu	Thr	Gln	Pro	Pro	Ser	Ala	Ser	Val	Asn	Val
				20					25					30		
10	Gly	Glu	Thr	Val	Lys	Ile	Thr	Cys	Ser	Gly	Asp	Gln	Leu	Pro	Lys	Tyr
			35					40					45			
15	Phe	Ala	Asp	Trp	Phe	His	Gln	Arg	Ser	Asp	Gln	Thr	Ile	Leu	Gln	Val
	50						55					60				
20	Ile	Tyr	Asp	Asp	Asn	Lys	Arg	Pro	Ser	Gly	Ile	Pro	Glu	Arg	Ile	Ser
	65					70					75					80
25	Gly	Ser	Ser	Ser	Gly	Thr	Thr	Ala	Thr	Leu	Thr	Ile	Arg	Asp	Val	Arg
					85					90					95	
30	Ala	Glu	Asp	Glu	Gly	Asp	Tyr	Tyr	Cys	Phe	Ser	Gly	Tyr	Val	Asp	Ser
				100					105					110		
35	Asp	Ser	Lys	Leu	Tyr	Val	Phe	Gly	Ser	Gly	Thr	Gln	Leu	Thr	Val	Leu
40																
45	Gly	Gly	Pro	Lys	Ser	Ser	Pro	Lys	Val	Thr	Val	Phe	Pro	Pro	Ser	Pro
		130					135					140				
50	Glu	Glu	Leu	Arg	Thr	Asn	Lys	Ala	Thr	Leu	Val	Cys	Leu	Val	Asn	Asp
	145					150					155				160	
55	Phe	Tyr	Pro	Gly	Ser	Ala	Thr	Val	Thr	Trp	Lys	Ala	Asn	Gly	Ala	Thr
				165						170					175	
60	Ile	Asn	Asp	Gly	Val	Lys	Thr	Thr	Lys	Pro	Ser	Lys	Gln	Gly	Gln	Asn
				180					185					190		
65	Tyr	Met	Thr	Ser	Ser	Tyr	Leu	Ser	Leu	Thr	Ala	Asp	Gln	Trp	Lys	Ser
			195					200					205			
70	His	Asn	Arg	Val	Ser	Cys	Gln	Val	Thr	His	Glu	Gly	Glu	Thr	Val	Glu
	210						215					220				
75	Lys	Ser	Leu	Ser	Pro	Ala	Glu	Cys	Leu							
	225					230										

Claims

1. An oncolytic virus comprising inserted in its genome a nucleic acid molecule encoding one or more immune checkpoint modulator(s), wherein said oncolytic virus is an oncolytic vaccinia virus defective for Ribonucleotide reductase (RR) activity resulting from inactivating mutations in the viral l4L gene.
2. The oncolytic virus of claim 1, wherein said oncolytic vaccinia virus is selected from the group of Elstree, Wyeth, Copenhagen and Western Reserve strains.
3. The oncolytic virus of claim 1 or 2, wherein said oncolytic vaccinia virus is defective for thymidine kinase (TK) resulting from inactivating mutations in the J2R viral gene.
4. The oncolytic virus of any one of claims 1 to 3, wherein said oncolytic vaccinia virus further comprises at least one therapeutic gene inserted in the viral genome, preferably said therapeutic gene is selected from the group consisting of genes encoding suicide gene products and genes encoding immunostimulatory proteins.
5. The oncolytic virus of claim 4, wherein said suicide gene is selected from the group consisting of genes coding protein having a cytosine deaminase (CDase) activity, a thymidine kinase activity, an uracil phosphoribosyl transferase (UPRTase) activity, a purine nucleoside phosphorylase activity and a thymidylate kinase activity.
6. The oncolytic virus of claim 5, wherein said suicide gene product has CDase and UPRTase activities, and preferably is selected from the group consisting of codA::upp, FCY1::FUR1 and FCY1::FUR1[Delta] 105 (FCU1) and FCU1-8 polypeptides.
7. The oncolytic virus of claim 5 or 6, wherein said oncolytic virus is a vaccinia virus defective for both TK and RR activities and comprising inserted into its genome the therapeutic FCU1 suicide gene.
8. The oncolytic virus of claim 4, wherein said immunostimulatory protein is an interleukin or a colony-stimulating factor, with a specific preference for GM-CSF.
9. The oncolytic virus of claim 8, wherein said oncolytic virus is a vaccinia virus defective for TK activity and comprising inserted into its genome the therapeutic human GM-CSF.
10. The oncolytic virus of any one of claims 1 to 9, wherein said one or more immune checkpoint modulator(s) is selected from the group consisting of peptide ligands, soluble domains of natural receptors, RNAi, antisense molecules, antibodies and protein scaffolds, and wherein said one or more immune checkpoint modulator(s) antagonizes at least partially the activity of inhibitory immune checkpoint(s), in particular those mediated by any of the following PD-1, PD-L1, PD-L2, LAG3, Tim3, BTLA and CTLA4.
11. The oncolytic virus of claim 10, wherein said one or more immune checkpoint modulator(s) comprises :
 - a) an antibody that specifically binds to human PD-1 and in particular an anti-PD-1 antibody selected from the group consisting of Nivolumab, Pembrolizumab and pidilizumab;
 - b) an antibody that specifically binds to human PD-L1 and in particular an anti PD-L1 antibody selected from the group consisting of MPDL3280A and BMS-936559; or
 - c) an antibody that specifically binds to human CTLA-4 and in particular an anti CTLA4 antibody selected from the group consisting of ipilimumab, tremelimumab and single chain anti-CTLA4 antibodies.
12. A pharmaceutical composition comprising an effective amount of the oncolytic virus of any one of claims 1 to 11 and a pharmaceutical acceptable vehicle.
13. The pharmaceutical composition of claim 12 comprising from approximately 10^7 pfu to approximately 5×10^9 pfu of said oncolytic virus.
14. The pharmaceutical composition of claim 12 or 13 which is formulated for parenteral administration.
15. The oncolytic virus of any one of claims 1 to 11 or the pharmaceutical composition of any one of claims 12 to 14,

for use for treating a proliferative disease, preferably a cancer, and more preferably a cancer selected from the group consisting of melanoma, renal cancer, prostate cancer, breast cancer, colorectal cancer, lung cancer and liver cancer.

16. The oncolytic virus or the pharmaceutical composition for use according to claim 15, wherein said oncolytic virus is administered by intravenous or intratumoral route.
17. The oncolytic virus or the pharmaceutical composition for use according to claim 16, which comprises from 2 to 5 intravenous or intratumoral administrations of 10^8 or 10^9 pfu of oncolytic vaccinia virus at approximately 1 or 2 weeks interval.
18. The oncolytic virus or the pharmaceutical composition for use according to any one of claims 15 to 17, which further comprises administration of a prodrug and/or a substance effective in anticancer therapy.

Patentansprüche

1. Onkolytisches Virus, das eingefügt in seinem Genom ein Nukleinsäuremolekül enthält, das einen oder mehrere Immun-Kontrollpunkt-Modulator(en) codiert, wobei das onkolytische Virus ein onkolytisches Vaccinia-Virus ist, das fehlerhaft für Ribonukleotid-Reduktase-(RR)-Aktivität ist, was aus inaktivierenden Mutationen im viralen I4L-Gen resultiert.
2. Onkolytisches Virus nach Anspruch 1, wobei das onkolytische Vaccinia-Virus aus der Gruppe bestehend aus Elstree-, Wyeth-, Copenhagen- und Western Reserve-Stämmen ausgewählt wird.
3. Onkolytisches Virus nach Anspruch 1 oder 2, wobei das onkolytische Vaccinia-Virus fehlerhaft für die Thymidinkinase (TK) ist, was aus inaktivierenden Mutationen im viralen J2R-Gen resultiert.
4. Onkolytisches Virus nach Anspruch 1 bis 3, wobei das onkolytische Vaccinia-Virus ferner mindestens ein therapeutisches Gen enthält, das in das virale Genom eingefügt ist, das therapeutische Gen wird vorzugsweise aus der Gruppe bestehend aus Genen ausgewählt, die Suizid-Genprodukte kodieren, und aus Genen, die immunstimulatorische Proteine kodieren.
5. Onkolytisches Virus nach Anspruch 4, wobei das Suizid-Gen aus der Gruppe ausgewählt wird, die aus Genen bestehen, die Protein kodieren, welches eine Cytosin-Deaminase-(CDase)-Aktivität, eine Thymidinkinase-Aktivität, eine Uracil-Phosphoribosyltransferase-(UPRTase)-Aktivität, eine Purinnukleosid-Phosphorylase-Aktivität und eine Thymidylatkinase-Aktivität haben.
6. Onkolytisches Virus nach Anspruch 5, wobei das Suizid-Genprodukt CDase- und UPRTase-Aktivitäten hat und vorzugsweise ausgewählt wird aus der Gruppe, die aus codA::upp, FCY1::FUR1 und FCY1::FUR1[Delta]105 (FCU1) und FCU1-8 Polypeptiden besteht.
7. Onkolytisches Virus nach Anspruch 5 oder 6, wobei das onkolytische Virus ein Vaccinia-Virus ist, das fehlerhaft sowohl für TK- und RR-Aktivitäten ist und, eingefügt in sein Genom, das therapeutische FCU1-Suizidgen enthält.
8. Onkolytisches Virus nach Anspruch 4, wobei das immunstimulatorische Protein ein Interleukin oder ein koloniestimulierender Faktor ist, mit einer speziellen Präferenz für GM-CSF.
9. Onkolytisches Virus nach Anspruch 8, wobei das onkolytische Virus ein Vaccinia-Virus ist, das fehlerhaft für TK-Aktivität ist und, eingefügt in sein Genom, das therapeutische humane GM-CSF enthält.
10. Onkolytisches Virus nach einem der Ansprüche 1 bis 9, wobei der eine oder die mehreren Immun-Kontrollpunkt-Modulator(en) aus der Gruppe ausgewählt wird/werden, die aus Peptidliganden, löslichen Domänen von natürlichen Rezeptoren, RNAi, Antisense-Molekülen, Antikörpern und Proteingerüsten besteht, und wobei der eine oder die mehreren Immun-Kontrollpunkt-Modulator(en) zumindest teilweise der Aktivität von inhibitorischen Immun-Kontrollpunkt(en) entgegenwirken, insbesondere denjenigen, die durch ein Element der folgenden vermittelt werden: PD-1, PD-L1, PD-L2, LAG3, Tim3, BTLA und CTLA4.

11. Onkolytisches Virus nach Anspruch 10, wobei der eine oder die mehreren Immun-Kontrollpunkt-Modulator(en) umfasst/umfassen:

- a) einen Antikörper, der sich insbesondere an menschliches PD-1 und insbesondere an einen Anti-PD-1-Antikörper bindet, der aus der Gruppe ausgewählt wird, die besteht aus Nivolumab, Pembrolizumab und Pidilizumab;
- b) einen Antikörper, der sich insbesondere an menschliches PD-L1 und insbesondere an einen Anti-PD-L1-Antikörper bindet, der aus der Gruppe ausgewählt wird, die besteht aus MPDL3280A und BMS-936559; oder
- c) einen Antikörper, der sich insbesondere an menschliches CTLA-4 und insbesondere an einen Anti-CTLA4-Antikörper bindet, der aus der Gruppe ausgewählt wird, die besteht aus Ipilimumab, Tremelimumab und einkettigen Anti-CTLA4-Antikörpern.

12. Pharmazeutische Zusammensetzung, die eine effektive Menge des onkolytischen Virus nach einem der Ansprüche 1 bis 11 und einen pharmazeutisch akzeptablen Träger enthält.

13. Pharmazeutische Zusammensetzung nach Anspruch 12, die von ca. 10⁷ PFU bis ca. 5 x 10⁹ PFU des onkolytischen Virus umfasst.

14. Pharmazeutische Zusammensetzung nach Anspruch 12 oder 13, die zur parenteralen Verabreichung formuliert ist.

15. Onkolytisches Virus nach einem der Ansprüche 1 bis 11 oder die pharmazeutische Zusammensetzung nach einem der Ansprüche 12 bis 14, zur Verwendung bei der Behandlung einer proliferativen Erkrankung, vorzugsweise eines Krebstumors, der aus der Gruppe ausgewählt wird, die aus Melanom, Nierenkrebs, Prostatakrebs, Brustkrebs, Kolorektalkarzinom, Lungenkrebs und Leberkrebs besteht.

16. Onkolytisches Virus oder die pharmazeutische Zusammensetzung zur Verwendung nach Anspruch 15, wobei das onkolytische Virus auf intravenösem oder intratumoralem Weg verabreicht wird.

17. Onkolytisches Virus oder die pharmazeutische Zusammensetzung zur Verwendung nach Anspruch 16, die 2 bis 5 intravenöse oder intratumorale Verabreichungen von 10⁸ oder 10⁹ PFU des onkolytischen Vaccinia-Virus in Intervallen von ca. 1 oder 2 Wochen umfasst.

18. Onkolytisches Virus oder die pharmazeutische Zusammensetzung zur Verwendung nach einem der Ansprüche 15 bis 17, die ferner die Verabreichung eines Prodrugs und/oder einer Substanz umfasst, die bei der Antikrebstherapie effektiv ist.

Revendications

1. Virus oncolytique comprenant insérée dans son génome une molécule d'acide nucléique codant un ou plusieurs modulateur(s) de point de contrôle d'immunité, dans lequel ledit virus oncolytique est un virus de la vaccine oncolytique défectueux pour l'activité de ribonucléotide réductase (RR) en résultat de mutations d'inactivation dans le gène I4L viral.

2. Virus oncolytique de la revendication 1, dans lequel ledit virus de la vaccine oncolytique est choisi dans le groupe des souches Elstree, Wyeth, Copenhagen et Western Reserve.

3. Virus oncolytique de la revendication 1 ou 2, dans lequel ledit virus de la vaccine oncolytique est défectueux pour la thymidine kinase (TK) en résultat de mutations d'inactivation dans le gène viral J2R.

4. Virus oncolytique de l'une quelconque des revendications 1 à 3, dans lequel ledit virus de la vaccine oncolytique comprend en outre au moins un gène thérapeutique inséré dans le génome viral, de préférence ledit gène thérapeutique est choisi dans le groupe constitué par les gènes codant les produits de gène suicide et les gènes codant les protéines immunostimulantes.

5. Virus oncolytique de la revendication 4, dans lequel ledit gène suicide est choisi dans le groupe constitué par les gènes codant une protéine ayant une activité de cytosine désaminase (CDase), une activité de thymidine kinase, une activité d'uracile phosphoribosyle transférase (UPRTase), une activité de purine nucléoside phosphorylase et une activité de thymidylate kinase.

6. Virus oncolytique de la revendication 5, dans lequel ledit produit de gène suicide a des activités de CDase et d'UPRTase, et de préférence est choisi dans le groupe constitué par les polypeptides codA::upp, FCY1::FUR1 et FCY1::FUR1[Delta] 105 (FCU1) et FCU1-8.
- 5 7. Virus oncolytique de la revendication 5 ou 6, dans lequel ledit virus oncolytique est un virus de la vaccine oncolytique défectueux à la fois pour les activités de TK et de RR et comprenant inséré dans son génome le gène suicide thérapeutique FCU1.
8. Virus oncolytique de la revendication 4, dans lequel ladite protéine immunostimulante est une interleukine ou un
10 facteur stimulant les colonies, avec une préférence spécifique pour GM-CSF.
9. Virus oncolytique de la revendication 8, dans lequel ledit virus oncolytique est un virus de la vaccine oncolytique défectueux pour l'activité de TK et comprenant inséré dans son génome le GM-CSF humain thérapeutique.
- 15 10. Virus oncolytique de l'une quelconque des revendications 1 à 9, dans lequel lesdits un ou plusieurs modulateurs de point de contrôle d'immunité sont choisis dans le groupe constitué par les ligands peptidiques, les domaines solubles de récepteurs naturels, les ARNi, les molécules antisens, les anticorps et les charpentes protéiques, et dans lequel lesdits un ou plusieurs modulateurs de point de contrôle d'immunité antagonisent au moins partiellement l'activité de point(s) de contrôle d'immunité inhibiteur(s), en particulier ceux médiés par l'un quelconque des
20 suivants : PD-1, PD-L1, PD-L2, LAG3, Tim3, BTLA et CTLA4.
11. Virus oncolytique de la revendication 10, dans lequel lesdits un ou plusieurs modulateur(s) de point de contrôle d'immunité comprennent :
25 a) un anticorps qui se lie spécifiquement au PD-1 humain et en particulier un anticorps anti-PD-1 choisi dans le groupe constitué par le nivolumab, le pembrolizumab et le pidilizumab ;
b) un anticorps qui se lie spécifiquement au PD-L1 humain et en particulier un anticorps anti-PD-L1 choisi dans le groupe constitué par MPDL3280A et BMS-936559 ; ou
c) un anticorps qui se lie spécifiquement au CTLA-4 humain et en particulier un anticorps anti-CTLA4 choisi
30 dans le groupe constitué par l'ipilimumab, le trémélimumab et les anticorps anti-CTLA4 à une seule chaîne.
12. Composition pharmaceutique comprenant une quantité efficace du virus oncolytique de l'une quelconque des revendications 1 à 11 et un véhicule pharmaceutiquement acceptable.
- 35 13. Composition pharmaceutique de la revendication 12, comprenant d'environ 10^7 pfu à environ 5×10^9 pfu dudit virus oncolytique.
14. Composition pharmaceutique de la revendication 12 ou 13, qui est formulée pour une administration par voie parentérale.
40
15. Virus oncolytique de l'une quelconque des revendications 1 à 11 ou composition pharmaceutique selon l'une quelconque des revendications 12 à 14, pour une utilisation dans le traitement d'une maladie proliférative, de préférence un cancer, et mieux encore un cancer choisi dans le groupe constitué par un mélanome, un cancer rénal, un cancer de la prostate, un cancer du sein, un cancer colorectal, un cancer du poumon et un cancer du foie.
45
16. Virus oncolytique ou composition pharmaceutique pour une utilisation selon la revendication 15, dans lequel ledit virus oncolytique est administré par voie intraveineuse ou intratumorale.
17. Virus oncolytique ou composition pharmaceutique pour une utilisation selon la revendication 16, qui comprend de
50 2 à 5 administrations intraveineuses ou intratumorales de 10^8 ou 10^9 pfu de virus de la vaccine oncolytique à intervalles d'environ 1 ou 2 semaines.
18. Virus oncolytique ou composition pharmaceutique pour une utilisation selon l'une quelconque des revendications 15 à 17, qui comprend en outre l'administration d'un promédicament et/ou d'une substance efficace en thérapie
55 anticancéreuse.

Figure 1




Figure 2




Figure 3




Figure 4

Heavy chain J43 sequence:

MGLGLQWVFFVALLKGVHCEVRLLES GGGLVKPEGSLKLSCVASGFTFSD
YFMSWVRQAPGKGLEWVAHIYTKSYNYATYYSGSVKGRFTISRDDSRSMV
YLQMNNLRTE DTATYYCTRDGSGYPSLDFWGQGTQVTVSSATTTAPSVYP
LAPACDSTTSTTDVTLGCLVKGYFPEPVTVSWNSGALTSGVHTFPSVLH
SGLYSLSSSVTPSSTWPKQPITCNVAHPASSTKVDKKIEPRTD TDCPN
PPDPCPTCPTDLLGGPSVFIFPPKPKDVL MISLTPKITCVVVDVSEEEP
DVQFNWYVNNVEDKTAQTETRQRQYNSTYRVVSVLPIKHQDWMSGKVFKC
KVNNNALPSPIEKTISKPRGQVRVPQIYTFPPPIEQTVKKDVSVCCLVTG
FLPQDIHVEWESNGQPQPEQNYKNTQPVLDSDGSYFLYSLNVPKSRWDQ
GDSFTCSVIHEALHNHHMTKTISRSLGN

Light chain J43 sequence:

MAWTPGIFMVLSYLTGSFSYELTQPPSASVNVGETVKITCSGDQLPKYFA
DWFHQRSDQTILQVIYDDNKRPSGIPERISGSSSGTTATLTIRDVRAEDE
GDYYCFSGYVDS DSKLYVFGSGTQLTVLGGPKSSPKVTVFPPSPEELRTN
KATLVCLVNDFYPGSATVTWKANGATINDGVKTTKPSKQGQNYMTSSYLS
LTADQWKSHNRVSCQVTHEGETVEKSLSPAEC

Figure 5




Figure 6A





Figure 6B



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 2014022138 A [0008]
- WO 2014047350 A [0008] [0076]
- WO 2009065546 A [0058] [0065]
- WO 2009065547 A [0058]
- EP 998568 A [0064] [0065]
- WO 9616183 A [0065]
- WO 200507857 A [0065]
- US 5225539 A [0070]
- US 5530101 A [0070]
- US 6180370 B [0070]
- WO 2012110360 A [0070]
- US 4946778 A [0072]
- US 5258498 A [0072]
- WO 2004004771 A [0076]
- WO 2004056875 A [0076]
- WO 2006121168 A [0076]
- WO 2008156712 A [0076]
- WO 2009014708 A [0076]
- WO 2009114335 A [0076]
- WO 2013043569 A [0076]
- EP 1907000 A [0077]
- US 20130177557 A [0078]
- US 8491895 B [0079]
- US 6984720 B [0079]
- US 8017114 B [0079]
- US 7109003 B [0079]
- US 8143379 B [0079]
- WO 9720574 A [0079]
- WO 2007123737 A [0079]
- US 5773578 A [0080]
- US 5457035 A [0081]
- US 7622444 B [0081]
- WO 03082919 A [0081]
- US 7291331 B [0081]
- WO 03106498 A [0081]
- US 5168062 A [0090]
- WO 9810088 A [0090]
- WO 9903885 A [0093]
- US 6686152 B [0094]
- WO 2005042728 A [0099]
- WO 2006108846 A [0099]
- WO 2008129058 A [0099]
- WO 2010130756 A [0099]
- WO 2012001075 A [0099]
- WO 2007147528 A [0099]
- WO 2008138533 A [0099]
- WO 2009100521 A [0099]
- WO 2010130753 A [0099]
- WO 2013022764 A [0099]
- WO 2009073569 A [0103]
- WO 9856415 A [0111]
- WO 2007147529 A [0111]
- WO 9802522 A [0112]
- WO 0166137 A [0112]
- WO 03053463 A [0112]
- WO 2007056847 A [0112]
- WO 2008114021 A [0112]
- WO 2014053571 A [0112]
- US 7858746 B [0132]
- EP 14306153 A [0179]

Non-patent literature cited in the description

- **LEACH et al.** *Science*, 1996, vol. 271, 1734-6 [0003]
- **HERMISTON.** *Curr. Opin. Mol. Ther.*, 2006, vol. 8, 322-30 [0004]
- **CHERNAJOVSKY et al.** *British Med. J.*, 2006, vol. 332, 170-2 [0004]
- **COHEN et al.** *Curr. Opin. Investig. Drugs*, 2001, vol. 2, 1770-5 [0006]
- **SENER et al.** *J. Clin. Oncol.*, 2009, vol. 27, 5763-71 [0006]
- **THORNE et al.** *J Clin Invest.*, 2007, vol. 117, 3350-8 [0007]
- Atlas of Protein Sequence and Structure. 1981, vol. 3, 482-9 [0031]
- **KIRN et al.** *Nat. Med.*, 2001, vol. 7, 781 [0042]
- **WONG et al.** *Viruses*, 2010, vol. 2, 78-106 [0042]
- **RUDIN et al.** *Clin. Cancer. Res.*, 2011, vol. 17 (4), 888-95 [0045]
- **STOJDL et al.** *Nat. Med.*, 2000, vol. 6 (7), 821-5 [0046]
- **STOJDL et al.** *Cancer Cell*, 2003, vol. 4 (4), 263-75 [0046]
- **PHUANGSAB et al.** *Cancer Lett.*, vol. 172 (1), 27-36 [0047]
- **LORENCE et al.** *Curr. Cancer Drug Targets*, 2007, vol. 7 (2), 157-67 [0047]
- **FREEMAN et al.** *Mol. Ther.*, 2006, vol. 13 (1), 221-8 [0047]
- **MARTUZA et al.** *Science*, 1991, vol. 252, 854-6 [0048]
- **BOVIATISIS et al.** *Gene Ther.*, vol. 1, 323-31 [0048]

- **MINETA et al.** *Cancer Res.*, 1994, vol. 54, 3363-66 [0048]
- **PYLES et al.** *J. Virol.*, 1994, vol. 68, 4963-72 [0048]
- **CHAMBERS et al.** *Proc. Natl. Acad. Sci. USA*, 1995, vol. 92, 1411-5 [0048]
- **GEEVARGHESE et al.** *Hum. Gene Ther.*, 2010, vol. 21 (9), 1119-28 [0048]
- **ANDTBACKA et al.** *J. Clin. Oncol.*, 2013, vol. 31 [0048]
- **MCDONALD et al.** *Breast Cancer Treat.*, 2006, vol. 99 (2), 177-84 [0049]
- **KAUFMANN et al.** *J. Invest. Dermatol.*, 2013, vol. 133 (4), 1034-42 [0049]
- **KHURI et al.** *Nat. Med.*, 2000, vol. 6 (8), 879-85 [0050]
- **XIA et al.** *Ai Zheng*, 2004, vol. 23 (12), 1666-70 [0050]
- **GUSE et al.** *Expert Opinion Biol. Ther.*, 2011, vol. 11 (5), 595-608 [0054]
- **GAMMON et al.** *PLOS Pathogens*, 2010, vol. 6 (7 [0056]
- **ZHANG et al.** *Cancer Res.*, 2007, vol. 67, 10038-46 [0057]
- **BROYLES et al.** *Virol.*, 1993, vol. 195, 863-5 [0057]
- **FOLOPPE et al.** *Gene Ther.*, 2008, vol. 15, 1361-71 [0058]
- **ANDERSEN et al.** *European J. Biochem.*, 1992, vol. 204, 51-56 [0064]
- **MARTINUSSEN et al.** *J. Bacteriol.*, 1994, vol. 176, 6457-63 [0064]
- **KIM et al.** *Biochem. Mol. Biol. Internat.*, 1997, vol. 41, 1117-24 [0064]
- **MARTINUSSEN et al.** *J. Bacteriol.*, 1995, vol. 177, 271-4 [0064]
- **KERN et al.** *Gene*, 1990, vol. 88, 149-57 [0064]
- **PRESTA et al.** *Cancer Res.*, 1997, vol. 57 (20), 4593-9 [0070]
- **BIRD et al.** *Science*, 1988, vol. 242, 423-6 [0072]
- **HUSTON et al.** *Proc. Natl. Acad. Sci. USA*, 1988, vol. 85, 5879-83 [0072]
- **AGATA et al.** *Int. Immunol.*, 1996, vol. 8, 765-72 [0076]
- **OKAZAKI et al.** *Curr. Opin. Immunol.*, 2002, vol. 14, 391779-82 [0076]
- **BENNETT et al.** *J. Immunol.*, 2003, vol. 170, 711-8 [0076]
- **TOPALIAN.** *Curr. Opin. Immunol.*, 2012, vol. 24, 207-12 [0076]
- **FREEMAN et al.** *J. Exp. Med.*, 2000, vol. 192, 1027-34 [0076]
- **CARTER et al.** *Eur. J. Immunol.*, 2002, vol. 32, 634-43 [0076]
- **DONG et al.** *Nat. Med.*, 2002, vol. 8, 787-9 [0076]
- **DONG et al.** *J. Mol. Med.*, 2003, vol. 81, 281-7 [0076]
- **BLANK et al.** *Cancer Immunol. Immunother.*, 2005, vol. 54, 307-314 [0076]
- **WANG et al.** *J. Exp. Med.*, 2011, vol. 208 (3), 577-592 [0078]
- **BRUNET et al.** *Nature*, 1987, vol. 328, 267-70 [0079]
- **DARIAVACH et al.** *Eur. J. Immunol.*, vol. 18, 1901-5 [0079]
- **QURESHI et al.** *Science*, 2011, vol. 332, 600-3 [0079]
- **HARLOW ; LANE.** *Antibodies-A laboratory manual.* Cold Spring Harbor Laboratory, 1988 [0084]
- **KOHLER ; MILSTEIN.** *Nature*, 1975, vol. 256, 495-7 [0084]
- **COTE et al.** *Proc. Natl. Acad. Sci. USA*, 1983, vol. 80, 2026-30 [0084]
- **COLE et al.** *Monoclonal antibodies and Cancer Therapy.* Alan Liss, 77-96 [0084]
- **SAMBROOK et al.** *Molecular Cloning-A Laboratory Manual.* Cold Spring Harbor Laboratory, 2001 [0085]
- **CHARTIER et al.** *J. Virol.*, 1996, vol. 70, 4805-10 [0085]
- **PAUL et al.** *Cancer gene Ther.*, 2002, vol. 9, 470-7 [0085]
- **ADRA et al.** *Gene*, 1987, vol. 60, 65-74 [0090]
- **ERBS et al.** *Cancer Gene Ther.*, 2008, vol. 15 (1), 18-28 [0090]
- **CHAKRABARTI et al.** *Biotechniques*, 1997, vol. 23, 1094-7 [0090]
- **HAMMOND et al.** *J. Virol Methods*, 1997, vol. 66, 135-8 [0090]
- **KUMAR ; BOYLE.** *Virology*, 1990, vol. 179, 151-8 [0090]
- **BRANDLER ; TANGY.** *CIMID*, 2008, vol. 31, 271 [0090]
- **GRAHAM et al.** *J. Gen. Virol.*, 1997, vol. 36, 59-72 [0099]
- **FALLAUX et al.** *Human Gene Ther.*, 1998, vol. 9, 1909-17 [0099]
- **WIGLER et al.** *Proc. Natl. Acad. Sci. USA*, 1980, vol. 77, 3567 [0100]
- **O'HARE et al.** *Proc. Natl. Acad. Sci. USA*, 1981, vol. 78, 1527 [0100]
- **MULLIGAN ; BERG.** *Proc. Natl. Acad. Sci. USA*, 1981, vol. 78, 2072 [0100]
- **COLBERRE-GARAPIN et al.** *J. Mol. Biol.*, 1981, vol. 150, 1 [0100]
- **SANTERRE et al.** *Gene*, 1984, vol. 30, 147 [0100]
- **REMINGTON.** *The Science and Practice of Pharmacy.* Lippincott [0108]
- **RIBI et al.** *Immunology and Immunopharmacology of Bacterial Endotoxins.* Plenum Publ. Corp, 1986, 407-419 [0111]
- **SUMINO et al.** *J. Virol.*, 1998, vol. 72, 4931 [0111]
- **SUADER.** *J. Am Acad Dermatol.*, 2000, vol. 43, S6 [0111]
- **SMORLESI.** *Gene Ther.*, 2005, vol. 12, 1324 [0111]
- **CHU et al.** *J. Exp. Med.*, 1997, vol. 186, 1623 [0111]
- **TRITEL et al.** *J. Immunol.*, 2003, vol. 171, 2358 [0111]
- **KRITSCH et al.** *J. Chromatogr Anal. Technol. Biomed. Life Sci.*, 2005, vol. 822, 263-70 [0111]
- **CAROLL et al.** *Virology*, 1997, vol. 238, 198-211 [0114]

- **IWA** et al. *Int. Immunol.*, 2005, vol. 17, 133-44 [0125]